Nabriva Therapeutics (NBRVF) 10-Q 5 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Jul. 31, 2021
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Entity File Number	001-37558
Entity Registrant Name	Nabriva Therapeutics plc
Entity Incorporation, State or Country Code	L2
Entity Address, Address Line One	25-28 North Wall Quay
Entity Address, Address Line Two	IFSC
Entity Address, City or Town	Dublin 1
Entity Address, Country	IE
Entity Tax Identification Number	00-0000000
Entity Address, Postal Zip Code	00000
City Area Code	353 1
Local Phone Number	649 2000
Title of 12(b) Security	Ordinary Shares, nominal value $0.01 per share
Trading Symbol	NBRV
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Shares Outstanding		49,738,883
Entity Central Index Key	0001641640
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 61,140	$ 41,359
Restricted cash	180	231
Short-term investments	16	16
Accounts receivable, net and other receivables	11,576	3,909
Inventory	10,113	5,823
Prepaid expenses	11,595	5,880
Total current assets	94,620	57,218
Property, plant and equipment, net	355	768
Intangible assets, net	54	80
Other non-current assets	380	370
Total assets	95,409	58,436
Current liabilities:
Current portion of long-term debt	1,823	2,041
Accounts payable	1,582	2,889
Accrued expense and other current liabilities	15,243	12,844
Deferred revenue	563	750
Total current liabilities	19,211	18,524
Non-current liabilities
Long-term debt	6,046	5,686
Other non-current liabilities	951	1,091
Total non-current liabilities	6,997	6,777
Total liabilities	26,208	25,301
Commitments and contingencies (Note 12)
Stockholders' Equity:
Ordinary shares, nominal value $0.01, 100,000,000 ordinary shares authorized at June 30, 2021; 21,078,781 and 49,737,552 issued and outstanding at December 31, 2020 and June 30, 2021, respectively	497	211
Preferred shares, nominal value $0.01, 100,000,000 shares authorized at June 30, 2021; None issued and outstanding
Additional paid in capital	640,638	579,123
Accumulated other comprehensive income	27	27
Accumulated deficit	(571,961)	(546,226)
Total stockholders' equity	69,201	33,135
Total liabilities and stockholders' equity	$ 95,409	$ 58,436

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Consolidated Balance Sheets
Ordinary stock, nominal value (in dollars per share)	$ 0.01	$ 0.01
Ordinary stock, authorized shares	100,000,000	100,000,000
Ordinary stock, issued shares	49,737,552	21,078,781
Ordinary stock, outstanding shares	49,737,552	21,078,781
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	100,000,000	100,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Total revenue	$ 8,243	$ 487	$ 10,772	$ 1,276
Operating expenses:
Cost of product sales	(3,621)	(368)	(3,683)	(376)
Research and development expenses	(3,150)	(3,831)	(7,018)	(8,775)
Selling, general and administrative expenses	(12,854)	(10,741)	(24,901)	(26,766)
Total operating expenses	(19,625)	(14,940)	(35,602)	(35,917)
Loss from operations	(11,382)	(14,453)	(24,830)	(34,641)
Other income (expense):
Other income (expense), net	470	(634)	348	164
Interest income	5	16	6	80
Interest expense	(241)	(251)	(463)	(1,275)
Loss on extinguishment of debt				(2,757)
Loss before income taxes	(11,148)	(15,322)	(24,939)	(38,429)
Income tax expense	(606)	(119)	(796)	(271)
Net loss	$ (11,754)	$ (15,441)	$ (25,735)	$ (38,700)
Loss per share
Basic (in dollars per share)	$ (0.29)	$ (1.37)	$ (0.77)	$ (3.73)
Diluted (in dollars per share)	$ (0.29)	$ (1.37)	$ (0.77)	$ (3.73)
Weighted average number of shares:
Basic	40,573,848	11,277,825	33,532,837	10,368,670
Diluted	40,573,848	11,277,825	33,532,837	10,368,670
Product revenue, net
Revenues:
Total revenue	$ 6,940	$ (48)	$ 7,070	$ 108
Collaboration revenue
Revenues:
Total revenue	813	7	2,815	152
Research premium and grant revenue
Revenues:
Total revenue	$ 490	$ 528	$ 887	$ 1,016

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock/Ordinary Shares	Additional paid in capital	Accumulated other comprehensive income	Accumulated deficit	Total
Stockholders' equity, beginning balance at Dec. 31, 2019	$ 95	$ 517,894	$ 27	$ (476,742)	$ 41,274
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2019	9,455
Consolidated Statements of Changes in Stockholders' Equity
Issuance of common stock & ordinary shares		186			186
Issuance of common stock & ordinary shares (in shares)	48
Shares issued in connection with the vesting of restricted share units (in shares)	8
Equity transaction costs		(39)			(39)
Stock-based compensation expense		1,752			1,752
Net loss				(23,259)	(23,259)
Stockholders' equity, ending balance at Mar. 31, 2020	$ 95	519,793	27	(500,001)	19,914
Stockholders' equity, ending balance (in shares) at Mar. 31, 2020	9,511
Stockholders' equity, beginning balance at Dec. 31, 2019	$ 95	517,894	27	(476,742)	41,274
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2019	9,455
Consolidated Statements of Changes in Stockholders' Equity
Net loss					(38,700)
Stockholders' equity, ending balance at Jun. 30, 2020	$ 143	559,733	27	(515,442)	44,461
Stockholders' equity, ending balance (in shares) at Jun. 30, 2020	14,297
Stockholders' equity, beginning balance at Mar. 31, 2020	$ 95	519,793	27	(500,001)	19,914
Stockholders' equity, beginning balance (in shares) at Mar. 31, 2020	9,511
Consolidated Statements of Changes in Stockholders' Equity
Issuance of ordinary shares and warrants	$ 48	41,319			41,367
Issuance of ordinary shares and warrants (in shares)	4,758
Shares issued in connection with the vesting of restricted share units (in shares)	19
Shares issued in connection with the employee stock purchase plan		43			43
Shares issued in connection with the employee stock purchase plan (in shares)	9
Equity transaction costs		(2,709)			(2,709)
Stock-based compensation expense		1,287			1,287
Net loss				(15,441)	(15,441)
Stockholders' equity, ending balance at Jun. 30, 2020	$ 143	559,733	27	(515,442)	44,461
Stockholders' equity, ending balance (in shares) at Jun. 30, 2020	14,297
Stockholders' equity, beginning balance at Dec. 31, 2020	$ 211	579,123	27	(546,226)	33,135
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2020	21,079
Consolidated Statements of Changes in Stockholders' Equity
Issuance of common stock & ordinary shares	$ 143	37,097			37,240
Issuance of common stock & ordinary shares (in shares)	14,294
Shares issued in connection with the vesting of restricted share units		1			1
Shares issued in connection with the vesting of restricted share units (in shares)	40
Equity transaction costs		(2,325)			(2,325)
Stock-based compensation expense		921			921
Net loss				(13,981)	(13,981)
Stockholders' equity, ending balance at Mar. 31, 2021	$ 354	614,817	27	(560,207)	54,991
Stockholders' equity, ending balance (in shares) at Mar. 31, 2021	35,413
Stockholders' equity, beginning balance at Dec. 31, 2020	$ 211	579,123	27	(546,226)	33,135
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2020	21,079
Consolidated Statements of Changes in Stockholders' Equity
Net loss					(25,735)
Stockholders' equity, ending balance at Jun. 30, 2021	$ 497	640,638	27	(571,961)	69,201
Stockholders' equity, ending balance (in shares) at Jun. 30, 2021	49,738
Stockholders' equity, beginning balance at Mar. 31, 2021	$ 354	614,817	27	(560,207)	54,991
Stockholders' equity, beginning balance (in shares) at Mar. 31, 2021	35,413
Consolidated Statements of Changes in Stockholders' Equity
Issuance of common stock & ordinary shares	$ 142	25,997			26,139
Issuance of common stock & ordinary shares (in shares)	14,313
Shares issued in connection with the vesting of restricted share units	$ 1	(1)
Shares issued in connection with the vesting of restricted share units (in shares)	12
Equity transaction costs		(992)			(992)
Stock-based compensation expense		817			817
Net loss				(11,754)	(11,754)
Stockholders' equity, ending balance at Jun. 30, 2021	$ 497	$ 640,638	$ 27	$ (571,961)	$ 69,201
Stockholders' equity, ending balance (in shares) at Jun. 30, 2021	49,738

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (25,735)	$ (38,700)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income/expense, net	73	(15)
Non-cash interest income		3
Non-cash interest expense	249	218
Loss on extinguishment of debt		2,757
Depreciation and amortization expense	188	209
Amortization of right-of-use assets	281	171
Stock-based compensation	1,738	3,103
Other, net	16	39
Changes in operating assets and liabilities:
Increase/(decrease) in other non-current assets	(10)	10
Increase in accounts receivable, net and other receivables and prepaid expenses	(13,382)	(3,247)
Increase in inventory	(4,290)	(4,514)
Decrease in accounts payable	(1,249)	(1,950)
Increase/(decrease) in accrued expenses and other liabilities	1,630	(3,427)
Decrease in deferred revenue	(187)
Increase/(decrease) in other non-current liabilities	(192)	4
Decrease in income tax liabilities	670	(33)
Net cash used in operating activities	(40,200)	(45,372)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(18)	(85)
Changes in restricted cash	(51)	(163)
Net cash used in investing activities	(69)	(248)
Cash flows from financing activities
Proceeds from issuance of ordinary shares and warrants	25,462	38,414
Proceeds from at-the-market facility	37,970	3,688
Proceeds from employee stock purchase plan		43
Repayments of long-term borrowings		(30,000)
Equity transaction costs	(3,276)	(2,977)
Net cash provided by financing activities	60,156	9,168
Effects of exchange rate changes on the balance of cash held in foreign currencies	(157)	(70)
Net increase/(decrease) in cash, cash equivalents and restricted cash	19,730	(36,522)
Cash, cash equivalents, and restricted cash at beginning of period	41,590	86,411
Cash, cash equivalents and restricted cash at end of period	61,320	49,889
Supplemental disclosure of cash flow information:
Interest paid	248	1,147
Equity transaction costs included in accounts payable and accrued expenses	$ 806	$ 319

Organization and Business Activ

Organization and Business Activities	6 Months Ended
	Jun. 30, 2021
Organization and Business Activities
Organization and Business Activities	​ 1. Organization and Business Activities Nabriva Therapeutics plc, or Nabriva Ireland, together with its wholly owned and consolidated subsidiaries, Nabriva Therapeutics GmbH, or Nabriva Austria, Nabriva Therapeutics US, Inc., Zavante Therapeutics, Inc., and Nabriva Therapeutics Ireland DAC, collectively, Nabriva, or the Company, is a biopharmaceutical company engaged in the commercialization and development of novel anti-infective agents to treat serious infections. The Company’s headquarters are located at 25-28 North Wall Quay, Dublin, Ireland. Throughout these notes to the consolidated financial statements, unless the context requires otherwise, all references to “Nabriva,” “the Company” or similar terms refer to Nabriva Therapeutics plc, together with its consolidated subsidiaries. In May 2021, the Company and Sumitomo Pharmaceuticals (Suzhou) announced positive topline results from Sumitomo Pharmaceuticals (Suzhou)’s Phase 3 clinical trial of lefamulin in Chinese adults with community-acquired bacterial pneumonia, or CABP. Sumitomo Pharmaceuticals (Suzhou)’s multi-center, randomized, double-blind trial was designed to evaluate the safety and efficacy of intravenous, or IV, to oral lefamulin compared to IV/oral moxifloxacin in 125 subjects with CABP. The results were similar to those observed in the global Phase 3 LEAP 1 and LEAP 2 clinical trials of lefamulin conducted by the Company. Consistent with previously reported clinical trial results, lefamulin was observed to be generally well-tolerated, with an overall rate of treatment-emergent adverse events, or TEAEs, comparable to that of moxifloxacin. The vast majority of TEAEs in both treatment arms were mild-to-moderate in severity, with serious adverse events occurring in 4% of lefamulin-treated patients and 10% of moxifloxacin-treated patients. TEAEs leading to discontinuation were uncommon and observed in just 5% of subjects in both treatment arms. In September 2020, the Centers for Medicare & Medicaid Services, or CMS, granted a new technology add-on payment, or NTAP, for XENLETA® (lefamulin) for injection, when administered in the hospital inpatient setting. Both the intravenous, or IV and oral formulations of XENLETA were granted Qualified Infectious Disease Product, or QIDP, and Fast Track designation by the U.S. Food and Drug Administration, or FDA. CONTEPO was granted an NTAP making it the first QIDP antibiotic to be granted conditional NTAP approval prior to receiving FDA approval. CONTEPO was granted QIDP and Fast Track Designation by the FDA for the treatment of complicated urinary tract infections, or cUTIs, including acute pyelonephritis. In July 2020, the Company announced that the European Commission, or EC, issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired pneumonia, or CAP, in adults following a review by the European Medicines Agency, or EMA. The EMA approval of XENLETA in CAP patients when it is considered inappropriate to use antibacterial agents that are commonly recommended for initial treatment or when these agents have failed paves the way for the launch of XENLETA across the European Economic Area, or EEA, and United Kingdom, or U.K. The EC approved XENLETA for all countries of the EEA and U.K. Nabriva intends to work with a commercial partner to make XENLETA available to patients in the EEA and U.K. In July 2020, the Company announced that Sunovion Pharmaceuticals Canada Inc., or Sunovion, received approval from Health Canada to market oral and IV formulations of XENLETA® (lefamulin) for the treatment of CAP in adults, with the Notice of Compliance from Health Canada dated July 10, 2020. Nabriva entered into a license and commercialization agreement in March 2019 with Sunovion Pharmaceuticals Canada Inc. for XENLETA in Canada. In July 2020, the Company announced that it entered into a Sales Promotion and Distribution Agreement, or the Distribution Agreement, with MSD International GmbH, or MSD, and Merck Sharp & Dohme Corp., or Supplier, each a subsidiary of Merck & Co. Under the Distribution Agreement, MSD appointed the Company as its sole and exclusive distributor of certain products containing tedizolid phosphate as the active ingredient previously marketed and sold by Supplier and MSD under the trademark SIVEXTRO® for injection, intravenous use and oral use in the United States and its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible Gram-positive microorganisms. Nabriva has also engaged Amplity Health, a leading pharmaceutical contract commercial organization, to provide community-based commercial and sales services for SIVEXTRO and XENLETA® in the United States. In June 2020 the Company announced that WE Pharma Ltd., or WEP Clinical, a specialist pharmaceutical services company, had signed an exclusive agreement with the Company to supply XENLETA® (lefamulin) on a named patient or expanded access basis in certain countries outside of the US, China and Canada. The Named Patient Program, or NPP, is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available and have an unmet medical need. In September for XENLETA on August 19, 2019 for the treatment of adults with CABP. XENLETA is the first oral and IV treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. In July 2018, the Company acquired Zavante Therapeutics Inc., or Zavante, a biopharmaceutical company focused on developing CONTEPO (fosfomycin for injection), and entered into an Agreement and Plan of Merger, or the Merger Agreement. CONTEPO is potentially a first-in-class epoxide antibiotic for IV administration in the United States. The Company is developing CONTEPO IV for cUTI and may potentially develop XENLETA and CONTEPO for additional indications. In April 2019, the FDA issued a Complete Response Letter, or CRL, in connection with the Company’s NDA for CONTEPO for the treatment of cUTIs, including acute pyelonephritis, stating that it was unable to approve the application in its current form. The CRL requests that issues related to facility inspections and manufacturing deficiencies at Nabriva’s active pharmaceutical ingredient contract manufacturer be addressed prior to the FDA approving the NDA. The Company requested a “Type A” meeting with the FDA to discuss its findings and this meeting occurred in July 2019. As the FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the CRL, the purpose of the meeting was to discuss and gain clarity on the issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers that were described in the CRL and other matters pertaining to the steps required for the resubmission of the NDA for CONTEPO. The Company resubmitted its NDA in December 2019 and the FDA acknowledged the resubmission in January 2020. In June 2020, the FDA issued a second CRL on the NDA for CONTEPO. Although the Company’s European contract manufacturing partners were prepared for regulatory authority inspections, the CRL cites observations at the Company’s manufacturing partners that could not be resolved due to FDA’s inability to conduct onsite inspections because of travel restrictions caused by the COVID-19 pandemic. In general, previously identified product quality and facility inspection related observations at the Company’s contract manufacturing partners are required to be satisfactorily resolved before the NDA may be approved. The FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the second CRL. The Company’s contract manufacturers continue to interact with FDA to discuss its plans for conducting inspections at their sites. On October 30, 2020, the Company participated in a Type A meeting with the FDA to obtain any new information related to the FDA’s pending conduct of inspections of foreign manufacturers during the COVID-19 pandemic that has negatively impacted a number of FDA product reviews, including the CONTEPO NDA. On April 14, 2021, the FDA issued industry guidance on remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities during COVID-19 specifying that when it cannot perform a Pre-Approval Inspection, or PAI, or a Pre-License Inspection, or PLI, or when the FDA determines that it would be useful to supplement a planned inspection, the agency will consider using tools other than a physical inspection and select the most appropriate method to address the specific risks that justify the need for the PAI or PLI. On April 5, 2021, the FDA granted the Company’s request for an extension of the potential CONTEPO NDA resubmission until June 2022 and as a result, the Company is currently assessing the impact of the guidance and awaiting further clarity from the FDA before determining specific timing of the potential resubmission. The FDA released the Resiliency Roadmap for FDA Inspectional Oversight that describes the systematic approach that FDA will utilize to manage postponed inspections and other oversight activities. The prioritization plan considers public health risks related to conducting an inspection, such as the impact of the product’s availability on public health, as well as investigator safety and travel restrictions/advisories. In addition, the FDA informed the Company that, while they cannot predict when an inspection may occur and when the pandemic may prevent the FDA from completing inspections, tier 1 mission-critical inspections and tier 2 higher priority inspections, which includes pre-approval inspections, will continue to be prioritized going forward. CONTEPO has been granted Qualified Infectious Disease Product, or QIDP, and Fast Track designations by the FDA for the treatment of serious infections, including cUTI. However, the Company cannot predict when the CONTEPO NDA will be resubmitted or when CONTEPO would receive marketing approval, if at all. Liquidity Since its inception, the Company has incurred net losses and generated negative cash flows from its operations which has resulted in a significant accumulated deficit to date. The Company has financed its operations through the sale of equity securities, convertible and term debt financings and research and development support from governmental grants and proceeds from its licensing agreements. As of June 30, 2021, the Company had cash and cash equivalents, restricted cash and short-term investments of $61.3 million. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40 , Presentation of Financial Statements Going Concern The Company expects to continue to invest in critical commercial and medical affairs activities, its commitments per the agreement with Merck & Co., Inc., as well as investing in its supply chain for the commercialization of XENLETA, SIVEXTRO and the potential launch of CONTEPO. The Company expects to seek additional funding in future periods to support these activities. While the Company has raised capital in the past, the ability to raise capital in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of the Company’s ability to meet its obligations for the next twelve months. ​ In April 2020, the Company announced a restructuring of its hospital-based commercial sales force and transition to a community-based sales effort. The restructuring reduced costs to align with the capabilities of the Company’s sales effort with its strategic re-focus on making sales of XENLETA to community health care professionals. The termination of the sales force was timed, in part, to coincide with operational changes that were implemented by the Company in response to the outbreak of the novel coronavirus, SARS-CoV-2, causing the disease referred to as “COVID-19”. In response to the COVID-19 pandemic, the Company closed its administrative offices and shifted to a remote working business model. The Company implemented a work-from-home policy for all of its employees. The commercial and medical organizations suspended in-person interactions with physicians and customers and were restricted to conducting educational and promotional activities virtually. The Company has secured a new virtual and in-person sales effort with community-based expertise with Amplity Health, which is a Contract Sales Organization, to replace its hospital-based sale force. In September 2020, the Company began a small and focused sales effort for SIVEXTRO and XENLETA, by utilizing 15 sales representatives. The Company expanded this effort to 60 sales representatives in November 2020 and the Company may expand it further in 2021 . The Company’s expenses will increase if it suffers any regulatory delays or is required to conduct additional clinical trials to satisfy regulatory requirements. The Company has incurred and expects to continue to incur significant commercialization expenses related to its commitments per the agreement with Merck & Co., Inc., product sales, marketing, distribution and manufacturing for XENLETA, SIVEXTRO and CONTEPO, if approved. It is also uncertain when, if ever, the Company will generate sufficient revenues from product sales to achieve profitability. As a result, based on the Company’s available cash resources, the minimum cash required under the Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc., and in accordance with the requirements of ASC 205-40, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. A failure to raise the additional funding or to effectively implement cost reductions could harm the Company’s business, results of operations and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company may make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend or eliminate one or more research and development programs or its commercialization efforts. Based on its current operating plans, the Company expects that its existing cash, cash equivalents, restricted cash and short-term investments as of the date of this Quarterly Report on Form 10-Q will be sufficient to enable the Company to fund its operating expenses, debt service obligations and capital expenditure requirements substantially through the first quarter of 2022. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than expected. This estimate assumes, among other things, that the Company does not obtain any additional funding through grants and clinical trial support, collaboration agreements or equity or debt financings. This estimate also assumes that the Company remains in compliance with the covenants and no event of default occurs under the Loan Agreement. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. In June 2019, the Company entered into an Open Market Sale Agreement SM In May 2021, the Company entered into an Open Market Sale Agreement SM million, from time to time through Jefferies, by any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon entry into the New Sale Agreement, the Company’s existing Jefferies ATM Agreement was terminated. The Company did not incur any termination penalties as a result of the replacement of the Jefferies ATM Agreement. As of the effective date of the termination of the Jefferies ATM Agreement, the Company had sold an aggregate of 5,925,699 of its ordinary shares pursuant to the Jefferies ATM Agreement for aggregate gross proceeds of $33.7 million and net proceeds to the Company of $31.9 million, after deducting commissions and offering expenses payable by the Company. The $16.3 million of ordinary shares that had been available for sale pursuant to the Jefferies ATM Agreement remained unsold at the time of its replacement. The replacement of the Jefferies ATM Agreement terminated any future sales of ordinary shares through the Jefferies ATM Agreement. As of June 30, 2021, the Company has issued and sold an aggregate of 14,318,074 ordinary shares pursuant to the New Sale Agreement and received gross proceeds of $26.1 million and net proceeds of $25.1 million, after deducting commissions to Jefferies and other offering expenses. From July 1, 2021 and through the date of this filing, the Company did not sell any shares under the New Sale Agreement. In March 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to issue and sell in a registered direct offering (1) an aggregate of 9,761,010 ordinary shares, $0.01 nominal value per share, and accompanying warrants to purchase up to an aggregate of 4,880,505 ordinary shares and (2) pre-funded warrants to purchase up to an aggregate of 600,000 ordinary shares and accompanying ordinary share warrants to purchase up to an aggregate of 300,000 ordinary shares. Each share was issued and sold together with an accompanying ordinary share warrant at a combined price of $2.4525 , and each pre-funded warrant was issued and sold together with an accompanying ordinary share warrant at a combined price of $2.4425 . The proceeds to us from the offering were $25.4 million gross and $23.4 million net after deducting the placement agent’s fees and other estimated offering expenses. Each pre-funded warrant had an exercise price per ordinary share equal to $0.01 and each pre-funded warrant was exercised in full on the issuance date. Each ordinary share warrant has an exercise price per ordinary share equal to $2.39 , was exercisable on the date of issuance and will expire on the five-year anniversary of the date of issuance.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Preparation The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP, for interim financial information, and US Securities and Exchange Commission, or SEC, regulations for quarterly reporting. The unaudited consolidated financial statements include the accounts of Nabriva Therapeutics plc and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial information as of June 30, 2021 and for the three and six months ended June 30, 2020 and 2021 are unaudited. The December 31, 2020 balance sheet was derived from audited consolidated financial statements but does not include all disclosures required by US GAAP. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2021 and results of operations for the three and six months ended June 30, 2020 and 2021. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 contained in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 11, 2021. The Company’s significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company has not adopted any new accounting pronouncements for the six months ended June 30, 2021.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory
Inventory	3. Inventory Inventory is stated at the lower of cost or net realizable value. Inventory is valued on a first-in, first-out basis and consists primarily of material costs, third-party manufacturing costs, and related transportation costs along the Company's supply chain. The Company capitalizes inventory upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are recorded as research and development expense. Costs of drug product to be consumed in any current or future clinical trials will continue to be recognized as research and development expense and costs of sample inventory is recorded as selling, general and administrative expense. The Company reviews inventories for realization on a quarterly basis and would record provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value when necessary. As of June 30, 2021, the Company had a $0.9 million non-cash reserve for excess and obsolete finished goods inventory due to the uncertainty of commercial activities underlying XENLETA product sales. Inventory reported at December 31, 2020 and June 30, 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ December 31, ​ ​ June 30, (in thousands) ​ 2020 ​ ​ 2021 Raw materials $ 952 ​ $ 1,379 Work in process 4,608 ​ 7,014 Finished goods 263 ​ 1,721 Total Inventory $ 5,823 ​ $ 10,113 ​

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2021
Fair Value Measurement
Fair Value Measurement	4. Fair Value Measurement US GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. ● Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (as exchange rates). ● Level 3: Valuation techniques that include inputs for the asset or liability that are not based on observable market data (those are unobservable inputs) and significant to the overall fair value measurement. The following table presents the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ 16 ​ — ​ — ​ 16 Total Assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ ​ 16 ​ — ​ — ​ 16 Total Assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​ There were no transfers between Level 1 and 2 in the six months ended June 30, 2021 or the year ended December 31, 2020. There were no changes in valuation techniques during the six months ended June 30, 2021. As of June 30, 2021, and December 31, 2020, the Company did not hold any financial instruments as liabilities that were held at fair value. Other receivables and accounts payable are carried at their historical cost which approximates fair value due to their short-term nature.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2021
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	5. Accrued Expenses and Other Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ June 30, (in thousands) ​ 2020 ​ 2021 Research and development related costs ​ $ 1,055 ​ $ 814 Payroll and related costs ​ 4,049 ​ 3,747 Accounting, tax and audit services ​ 470 ​ 500 Manufacturing and inventory ​ ​ 4,779 ​ ​ 4,435 Accrued gross to net ​ ​ 662 ​ ​ 3,482 Other ​ 1,829 ​ 2,265 Total other current liabilities ​ $ 12,844 ​ $ 15,243 ​

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt
Debt	6. Debt In December 2018, the Company entered into the Loan Agreement by and among the Company, Nabriva Therapeutics Ireland DAC, and certain other subsidiaries of the Company and Hercules Capital, Inc., or Hercules, pursuant to which a term loan of up to an aggregate principal amount of $75.0 million was available to the Company. The Loan Agreement initially provided for an initial term loan advance of $25.0 million, which was funded in December 2018, and, at the Company’s option and subject to the occurrence of certain funding conditions, several additional tranches of which $5.0 million became available upon the approval by the FDA of the NDA for XENLETA, which was drawn down. The other tranches are no longer available as their contingencies were not achieved. The Company may request a term loan advance of $5.0 million (“the Tranche Advance”) prior to December 31, 2021 subject to Hercules’s sole discretion. The term loan bears interest at an annual rate equal to the greater of 9.80% or 9.80% plus the prime rate of interest minus 5.50%. The Loan Agreement provided for interest-only payments through July 1, 2021 and repayment of the outstanding principal balance of the term loan thereafter in monthly installments through June 1, 2023 (the “Maturity Date”). In addition, the Company is required to pay a fee of 6.95% of the aggregate amount of advances under the Loan Agreement at the Maturity Date (the “End of Term Fee”). At the Company’s option, the Company may elect to prepay any portion of the outstanding term loan that is greater than or equal to $5.0 million by paying such portion of the principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% if the term loan is prepaid during the first 12 months following the initial closing, (ii) 2.0% if the term loan is prepaid after 12 months following the initial closing but before 24 months following the initial closing and (iii) 1.0 % if the term loan is prepaid any time thereafter but prior to the Maturity Date. On March 11, 2020, the Company entered into an amendment, or the Third Amendment, to its Loan Agreement with Hercules. Pursuant to the Amendment, the Company repaid $30.0 million of the $35.0 million in aggregate principal amount of debt outstanding under the Loan Agreement, or the Prepayment. The Company determined to enter into the Third Amendment following the effectiveness of a performance covenant in February 2020 under which it became obligated to either (1) achieve 80% of its net product revenue sales target over a trailing six-month period, or (2) maintain an amount of cash and cash equivalents in accounts pledged to Hercules plus a specified amount of eligible accounts receivables equal to the greater of the amount outstanding under the Loan Agreement or $40.0 million, or the Liquidity Requirement. Under the Third Amendment, the Company and Hercules agreed to defer the end of term loan charge payment of $2.1 million that would have otherwise become payable on the date of the Prepayment and to reduce the prepayment charge with respect to the Prepayment from $600,000 to $300,000 and to defer its payment, in each case, until June 1, 2023 or such earlier date on which all loans under the Loan Agreement are repaid or become due and payable. The Third Amendment also reset the revenue performance covenant to 70% of targeted revenue based on a revised net product revenue forecast and lowered the minimum liquidity requirement to $3.0 million in cash and cash equivalents, in each case, following the Prepayment. The new minimum liquidity requirement will not apply if CONTEPO receives regulatory approval from the U.S. Food and Drug Administration and the Company achieves at least 70% of its revised net product revenue targets under the Loan Agreement. On June 2, 2021, the Company entered into a further amendment, or the Fourth Amendment, to its Loan and Security Agreement with Hercules. Pursuant to the Fourth Amendment, the date on which the Company must commence repaying principal under the Loan Agreement was extended to April 1, 2022, or the Amortization Date, which date may be extended until July 1, 2022, subject to the receipt by the Company of a specified amount of additional net financing proceeds and the achievement of a specified product revenue milestone. Additionally, the time during which the Tranche Advance may be requested by the Company under the Loan Agreement, was extended until the Amortization Date. In addition, pursuant to the Fourth Amendment, the minimum liquidity requirement of $3.0 million in cash and cash equivalents will be waived at any time the Company has recognized $15.0 million of net product revenue during the applicable trailing three months . The Company’s obligations under the Loan Agreement are guaranteed by all current and future subsidiaries of the Company, and each of the Company and its subsidiaries has granted Hercules a security interest in all of their respective personal property, intellectual property and other assets owned or later acquired. The Loan Agreement also contains certain events of default, representations, warranties and covenants of the Company and its subsidiaries. For example, the Loan Agreement contains representations and covenants that, subject to exceptions, restrict the Company’s and its subsidiaries’ ability to do the following, among other things: declare dividends or redeem or repurchase equity interests; incur additional indebtedness and liens; make loans and investments; engage in mergers, acquisitions and asset sales; certain transactions with affiliates; undergo a change in control; and add or change business locations or settle in cash potential milestone payment obligations that may become payable by the Company in the future to former security holders of Zavante. The Company was in compliance with all of its Loan Agreement covenants at June 30, 2021. ​ The Loan Agreement also grants Hercules or its nominee an option to purchase up to an aggregate of $2.0 million of the Company’s equity securities, or instruments exercisable for or convertible into equity securities, sold to investors in any private financing upon the same terms and conditions afforded to such other investors for as long as there are amounts outstanding under the Loan Agreement. The Company incurred $1.3 million of costs in connection with the Loan Agreement which along with the initial fee of $0.7 million paid to Hercules were recorded as debt issuance cost and are being amortized as interest expense using the effective interest method over the term of the loan. In connection with the Third Amendment, the Company recognized a non-cash $2.7 million loss on the extinguishment of debt during the three months ended March 31, 2020 which represents the excess of the reacquisition price of the $30.0 million debt repaid over the net carrying amount of the extinguished debt. The carrying value of the term loan payable at June 30, 2021 includes the present value of the End of Term Fee and the Prepayment Fee. The End of Term Fee on the remaining $5.0 million principal balance is being accrued as additional interest expense using the effective interest method over the term of the loan. Long-term debt as December 31, 2020 and June 30, 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ ​ ​ December 31, ​ ​ June 30, (in thousands) ​ 2020 ​ 2021 Term loan payable $ 5,000 $ 5,000 End of term fee ​ ​ 2,048 ​ ​ 2,188 Unamortized debt issuance costs ​ (206) ​ (193) Carrying value of term loan ​ ​ 6,842 ​ ​ 6,995 Other long-term debt ​ ​ 885 ​ ​ 874 Less: Amounts due within one year ​ ​ (2,041) ​ ​ (1,823) Total long-term debt $ 5,686 $ 6,046 ​ Maturities of long-term debt including the end of term fee as of June 30, 2021 were as follows: ​ ​ ​ ​ ​ (in thousands) ​ ​ ​ 2021 $ — 2022 ​ $ 3,795 2023 ​ $ 4,811 ​

Revenue

Revenue	6 Months Ended
	Jun. 30, 2021
Revenue
Revenue	7. Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, (in thousands) 2020 2021 2020 2021 Product revenue, net ​ $ (48) ​ $ 6,940 ​ $ 108 ​ $ 7,070 Collaboration revenues ​ ​ 7 ​ ​ 813 ​ ​ 152 ​ ​ 2,815 Research premium ​ ​ 301 ​ ​ 490 ​ ​ 591 ​ ​ 792 Government grants ​ 227 ​ — ​ 425 ​ 95 Total ​ $ 487 ​ $ 8,243 ​ $ 1,276 ​ $ 10,772 ​ Collaboration revenues for the six months ended June 30, 2021 include $1.6 million related to the restructured China Region License Agreement, a portion of which is recognized over the estimated period the manufacturing collaboration and regulatory support will be provided to Sumitomo Pharmaceuticals (Suzhou), as well as $1.2 million of the Company’s share of revenues associated with the SIVEXTRO distribution agreement with Merck & Co., Inc. through April 11, 2021 (see Note 11). The Company sells its products to pharmaceutical wholesalers/distributors (i.e., the Company’s customers). The Company’s wholesalers/distributors in turn sell the Company’s products directly to clinics, hospitals, and private practices. Revenue from the Company’s product sales is recognized as physical delivery of product occurs (when the Company’s customer obtains control of the product), in return for agreed-upon consideration. For the six months ended June 30, 2020 and 2021 XENLETA product revenues, gross were $398 thousand and $310 thousand, respectively, including revenues from the Company´s Named Patient Program of $17 thousand for the six months ended June 30, 2021. SIVEXTRO product revenues, gross were $10.3 million since the Company began exclusive distribution of SIVEXTRO under its own National Drug Code, or NDC, on April 12, 2021. The Company´s product revenues, gross (i.e., delivered units multiplied by the contractual price per unit) are reduced by the corresponding gross-to-net, or GTN, estimates, resulting in the Company´s reported “product revenues, net” in the accompanying consolidated statements of operations. These GTN estimates are based upon information received from external sources (such as written or oral information obtained from the Company´s customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred may be materially above or below the amount initially estimated when product revenues are originally recorded, then requiring prospective adjustments to the Company’s reported product revenues, net. The following tables summarizes gross-to-net (“GTN”) adjustments for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, (in thousands) ​ 2020 2021 2020 2021 Product revenue, gross ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ SIVEXTRO ​ $ — ​ $ 10,287 ​ $ — ​ $ 10,287 XENLETA ​ ​ 149 ​ ​ 120 ​ ​ 398 ​ ​ 310 Total product revenue, gross ​ ​ 149 ​ 10,407 ​ 398 ​ 10,597 GTN accruals ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Chargebacks and cash discounts ​ (5) ​ (222) ​ (13) ​ (228) Medicaid and Medicare rebates ​ ​ (18) ​ ​ (1,003) ​ ​ (46) ​ ​ (1,018) Other returns, rebates, discounts and adjustments ​ ​ (35) ​ ​ (2,196) ​ ​ (92) ​ ​ (2,235) Total GTN accruals ​ ​ (58) ​ ​ (3,421) ​ ​ (151) ​ ​ (3,481) Product revenue ​ ​ 91 ​ ​ 6,986 ​ ​ 247 ​ ​ 7,116 Adjustments to prior period accruals ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns reserve (1) ​ ​ (349) ​ ​ (132) ​ ​ (349) ​ ​ (132) GTN accrual adjustments ​ ​ 210 ​ ​ 86 ​ ​ 210 ​ ​ 86 Product revenue, net ​ $ (48) $ 6,940 $ 108 $ 7,070 ​ (1) For the three and six months ended June 30, 2020, the Company recorded a returns reserve adjustment for slow-moving inventory, representing 50% of XENLETA IV inventory held at its Specialty Distributors, as well as an adjustment for returns from a single mail order specialty pharmacy. For the three and six months ended June 30, 2021, the Company recorded a returns reserve adjustment for shelf life expiration of certain XENLETA products.

Share-Based Payments

Share-Based Payments	6 Months Ended
	Jun. 30, 2021
Share-Based Payments
Share-Based Payments	8. Share-Based Payments Stock Option Plan 2015 On April 2, 2015, the Company’s shareholders, management board and supervisory board adopted the Stock Option Plan 2015, or the SOP 2015, as amended. With the approval of the 2017 Share Incentive Plan, there were no further options are available for grant under the SOP 2015. However, all outstanding awards under SOP 2015 will remain in effect and continue to be governed by the terms of the SOP 2015. Each vested option grants the beneficiary the right to acquire one share in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. During the second, third and fourth years of the vesting period, the remaining 75% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Options granted under the SOP 2015 have a term of no more than ten years from the beneficiary’s date of participation. The following table summarizes information regarding the Company’s stock option awards under the SOP 2015 for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in ​ intrinsic SOP 2015 ​ Options $ per share value Outstanding as of January 1, 2021 ​ 202,374 ​ 82.71 ​ Granted ​ — ​ — ​ ​ Exercised ​ — ​ — ​ ​ Forfeited ​ (32,824) 88.93 ​ ​ Outstanding as of June 30, 2021 ​ 169,550 81.51 ​ $ — Vested and exercisable as of June 30, 2021 ​ 169,141 81.48 ​ $ — ​ Stock-based compensation expense under the SOP 2015 was $0.3 million and $0.6 million for the three and six months ended June 30, 2020 and $38 thousand and $169 thousand for the three and six months ended June 30, 2021, respectively. The weighted average remaining contractual life of the options as of June 30, 2021 was 4.9 years. As of June 30, 2021, there was $3 thousand of total unrecognized compensation expense, related to unvested options granted under the SOP 2015, which will be recognized over the weighted-average remaining vesting period of 0.1 years. 2017 Share Incentive Plan On July 26, 2017, the Company’s board of directors adopted the 2017 Share Incentive Plan, or the 2017 Plan, and the shareholders approved the 2017 Plan at the Company’s Extraordinary General Meeting of Shareholders on September 15, 2017. Following shareholder approval of the 2017 Plan, the Company ceased making awards under the SOP 2015. The 2017 Plan permitted the award of share options (both incentive and nonstatutory options), share appreciation rights, or SARs, restricted shares, restricted share units, or RSUs, and other share-based awards to the Company’s employees, officers, directors, consultants and advisers. The 2017 Plan is administered by the Company’s board of directors. With the approval of the 2020 Share Incentive Plan, there were no further options are available for grant under the 2017 Plan. The following table summarizes information regarding the Company’s stock option awards under the 2017 Plan for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ ​ Aggregate ​ ​ ​ ​ price in $ ​ ​ intrinsic 2017 Plan Options per share ​ value Outstanding as of January 1, 2021 442,844 ​ 30.89 Granted — ​ — Exercised — ​ — Forfeited (101,204) ​ 32.82 ​ ​ Outstanding as of June 30, 2021 341,640 ​ 30.31 ​ $ — Vested and exercisable as of June 30, 2021 231,403 ​ 34.75 ​ $ — ​ Stock-based compensation expense for stock option awards under the 2017 Plan was $0.5 million and $1.1 million for the three and six months ended June 30, 2020 and $0.3 million and $0.6 million for the three and six months ended June 30, 2021, respectively. ​ The weighted average remaining contractual life of the options as of June 30, 2021 is 7.5 years. As of June 30, 2021, there was $1.4 million of total unrecognized compensation expense, related to unvested options granted under the 2017 Plan, which will be recognized over the weighted-average remaining vesting period of 1.2 years. Restricted Share Units (“RSUs”) Under the 2017 Plan, the Company granted RSUs which vest over a period of four years with 25% vesting upon the first anniversary of the grant date and on a monthly pro rata basis thereafter over the remaining three years. The Company also granted RSUs to certain employees that vest over a period of four years with 25% vesting upon the first anniversary of the grant date and on a monthly pro rata basis thereafter over the remaining three years. During 2018, the Company granted RSUs to certain employees where vesting of the RSUs was subject to FDA approval of an NDA for XENLETA. Fifty percent (50%) of each RSU award vested upon FDA approval, and the remaining fifty percent (50%) vested on the one- year anniversary of such approval. In connection with the FDA approval that was received in August 2019, the Company started recognizing compensation expense, as there was no compensation expense recognized on these awards prior to the FDA approval as it was determined that approval was not probable since it was outside of the Company’s control. Also during 2018, the Company granted RSUs to certain employees that have vested in three six-month increments beginning in May 2019 and ending in May 2020. Lastly, the Company granted RSUs in 2018 to certain employees where vesting of the RSUs is subject to FDA approval of an NDA for CONTEPO. Fifty percent (50%) of each RSU award will vest upon FDA approval, and the remaining fifty percent (50%) will vest on the one-year anniversary of such approval. The following table summarizes information regarding the Company´s RSU awards under the 2017 Plan for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ average fair 2017 Plan RSUs ​ value in $ per share Outstanding as of January 1, 2021 151,269 ​ 14.56 Granted — ​ — Vested and issued (42,752) ​ 13.98 Forfeited (30,640) ​ 13.62 Outstanding as of June 30, 2021 77,877 ​ 14.19 ​ Stock-based compensation expense for RSUs granted under the 2017 Plan was $0.4 million and $1.0 million for the three and six months ended June 30, 2020 and $0.1 million and $0.3 million for the three and six months ended June 30, 2021, respectively. ​ The Company has total unrecognized compensation costs of $0.4 million associated with RSUs which are expected to be recognized over the awards average remaining vesting period of 2.6 years. The fair value of RSU’s that vested during the six months ended June 30, 2021 was $0.2 million. ​ 2019 Inducement Share Incentive Plan On March 12, 2019, the Company’s board of directors adopted the 2019 Inducement Share Incentive Plan, or the 2019 Inducement Plan and, subject to the adjustment provisions of the 2019 Inducement Plan, reserved 200,000 ordinary shares for issuance pursuant to equity awards granted under the 2019 Inducement Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), awards under the 2019 Inducement Plan may only be made to individuals who were not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the Company), as an inducement material to the individuals’ entry into employment with the Company. On April 28, 2020, the board of directors resolved not to make any further awards under the 2019 Inducement Plan. The following table summarizes information regarding the Company’s stock option awards under the 2019 Inducement Plan for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2019 Inducement Plan Options per share value Outstanding as of January 1, 2021 25,815 ​ 19.04 ​ ​ Granted — ​ — ​ ​ Exercised — ​ — ​ ​ Forfeited (13,053) ​ 18.20 ​ ​ ​ Outstanding as of June 30, 2021 12,762 ​ 19.90 ​ $ — Vested and exercisable as of June 30, 2021 8,510 ​ 19.16 ​ $ — ​ Stock-based compensation expense under the 2019 Inducement Plan was less than $0.1 million for the three and six months ended June 30, 2020 and $7 thousand and $23 thousand for the three and six months ended June 30, 2021, respectively. ​ The weighted average remaining contractual life of the options as of June 30, 2021 was 8.2 As of June 30, 2021, there was $53 thousand of total unrecognized compensation expense, related to unvested options granted under the 2019 Inducement Plan, which will be recognized over the weighted-average remaining vesting period of 2.0 Inducement Awards Outside of the 2019 Inducement Plan In July 2018, the Company granted a non-statutory option to purchase 85,000 of its ordinary shares and 15,000 performance-based RSUs to the Company’s newly appointed Chief Executive Officer, or the CEO. These equity awards were granted outside of the 2017 Plan and the 2019 Inducement Plan, were approved by the Company’s compensation committee and board of directors and were made as an inducement material to the CEO entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price per share for the share option is $35.30 per share, and the option award has a ten-year term and will vest over a four-year period, with 25% of the shares underlying the award vesting on the first anniversary of the grant date and the remaining 75% of the shares underlying the option award to vest monthly over the subsequent 36-month period. The performance-based RSUs are subject to vesting as follows: 50% will vest upon certification by the board of directors of the receipt of approval by the FDA of an NDA for each of lefamulin and CONTEPO for any indication, and 50% will vest on the first anniversary of such certification by the board of directors, provided, in each case, the CEO is performing services to the Company on the applicable vesting dates. If the FDA does not approve an NDA for both lefamulin and CONTEPO by January 31, 2020, the performance-based RSUs will terminate in full. Since CONTEPO was not approved by this date the award was forfeited. The Company also issues non-statutory options to new employees upon the commencement of their employment. Stock-based compensation expense for the inducement awards granted outside of the 2019 Inducement Plan was $0.1 million and $0.2 million for the three and six months ended June 30, 2020, and $0.1 million and $0.2 million for the three and six months ended June 30, 2021. The performance-based RSUs had a grant date fair value of $3.53 per share and the options had a grant date fair value of $2.05 per share based on a Black Scholes option pricing model. No expense has been recognized to date on the performance based RSUs as it was determined that approval of CONTEPO is not probable since it is outside of the Company’s control. The weighted average remaining contractual life of the options as of June 30, 2021 was 7.1 As of June 30, 2021, there was $0.5 million of total unrecognized compensation expense, related to unvested inducement award options granted, which will be recognized over the weighted-average remaining vesting period of 1.1 years. 2020 Share Incentive Plan On March 4, 2020, the Company´s board of directors adopted the 2020 Share Incentive Plan, or the 2020 Plan, which was approved by the Company´s shareholders at the 2020 Annual General Meeting of Shareholders in July 2020, or 2020 AGM. As of the date of the 2020 AGM, the total number of ordinary shares reserved for issuance under the 2020 Plan was for the sum of 930,000 ordinary shares, plus the number of the Company´s ordinary shares that remained available for grant under the 2017 Plan as of immediately prior to the AGM and the number of ordinary shares subject to awards granted under the 2017 Plan and the Company´s Amended and Restated Stock Option Plan 2015, that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right. Following shareholder approval of the 2020 Plan, no further awards will be made under the 2017 Plan. The 2020 Plan provides for the grant of incentive share options, non-statutory share options, share appreciation rights, restricted share awards, restricted share units, other share-based and cash-based awards and performance awards. At June 30, 2021, 657,575 ordinary shares were available for future issuance under the 2020 Plan. The following table summarizes information regarding the Company’s stock option awards under the 2020 Plan for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2020 Plan Options per share value Outstanding as of January 1, 2021 296,805 ​ 10.18 ​ Granted 21,000 ​ 1.39 ​ Exercised — ​ — ​ Forfeited (107,325) ​ 5.70 ​ Outstanding as of June 30, 2021 210,480 ​ 9.87 ​ $ — Vested and exercisable as of June 30, 2021 — ​ — ​ $ — ​ Stock-based compensation expense for stock option awards under the 2020 Plan was $51 thousand and $65 thousand for the three and six months ended June 30, 2020 and $0.1 million and $0.2 million for the three and six months ended June 30, 2021, respectively. The options granted in the six months ended June 30, 2021 had a weighted average grant date fair value of $0.90 per share based on a Black Scholes option pricing model using the following assumptions. The significant inputs into the model were as follows: ​ ​ ​ ​ ​ ​ Input parameters ​ ​ Expected volatility 77.3 % Expected term of options (in years) 5.5 ​ Range of risk-free interest rate 1.0 % Dividend yield — ​ ​ The weighted average remaining contractual life of the options as of June 30, 2021 was 7.9 As of June 30, 2021, there was $0.6 million of total unrecognized compensation expense related to unvested options granted under the 2020 Plan, which will be recognized over the weighted-average remaining vesting period of 1.5 years. Restricted Share Units (“RSUs”) During 2020, the Company granted 45,977 RSUs to certain employees that vest in three six-month increments beginning in January 2021 and ending in January 2022, with a grant date fair value of $7.88 per share. Also during 2020, the Company granted 43,125 RSUs to certain employees with a grant date fair value of $5.30 per share, where vesting of the RSUs was subject to individual performance goals. During the six months ended June 30, 2021, the Company granted 341,935 RSUs to certain employees that vest in annual increments beginning January 2022 and ending in January 2025. Additionally, the Company granted 7,000 RSUs to each our former CMO and former CFO, 2021 Inducement Share Incentive Plan ​ On December 9, 2020, the Company´s board of directors adopted without stockholder approval the 2021 Inducement Share Incentive Plan (the “2021 Inducement Plan”) and, subject to the adjustment provisions of the 2021 Inducement Plan, reserved 200,000 ordinary shares for issuance pursuant to equity awards granted under the 2021 Inducement Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), awards under the 2021 Inducement Plan may only be made to individuals who were not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the company), as an inducement material to the individuals’ entry into employment with the Company. ​ Options and SARs granted will be exercisable at such times and subject to such terms and conditions as the board may specify in the applicable option agreement; provided, however, that no option or SAR will be granted with a term in excess of ten years. The board will also determine the terms and conditions of restricted shares and RSUs, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. ​ The following table summarizes information regarding the Company’s stock option awards under the 2021 Inducement Plan for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2021 Inducement Plan Options per share value Outstanding as of January 1, 2021 — — ​ Granted ​ 129,250 ​ 1.66 ​ Exercised ​ — ​ — ​ Forfeited ​ — ​ — ​ Outstanding as of June 30, 2021 129,250 ​ 1.66 ​ $ — Vested and exercisable as of June 30, 2021 — — ​ $ — ​ ​ Stock-based compensation expense recognized for the 2021 Inducement Plan was $8 thousand for the three and six months ended June 30, 2021. The options granted in the six months ended June 30, 2021 had a weighted average grant date fair value of $1.09 per share based on a Black Scholes option pricing model using the following assumptions. The significant inputs into the model were as follows: ​ ​ ​ ​ Input parameters Expected volatility 75.3% - 76.3% Expected term of options (in years) 6.1 Risk-free interest rate 1.02% - 1.16% Dividend yield — ​ ​ At June 30, 2021, 70,750 ordinary shares were available for future issuance under the 2021 Inducement Plan. The weighted average remaining contractual life of the options as of June 30, 2021 was 9.1 years. As of June 30, 2021, there was $142 thousand of total unrecognized compensation expense related to unvested options granted under the 2021 Inducement Plan, which will be recognized over the weighted-average remaining vesting period of 4.0 years. ​ Employee Stock Purchase Plan The Company’s board of directors adopted, and in August 2018 Company’s stockholders approved, the 2018 employee stock purchase plan, or the 2018 ESPP. The maximum aggregate number of shares of ordinary shares that may be purchased under the 2018 ESPP is 50,000 shares, or the ESPP Share Pool, subject to adjustment as provided for in the 2018 ESPP. The ESPP Share Pool available as of December 31, 2020, represented less than 0.1% of the total number of shares of ordinary shares outstanding as of December 31, 2020. The 2018 ESPP allows eligible employees to purchase shares at a 15% discount to the lower of the closing share price at the beginning and end of the six-month offering periods commencing November 1 and ending April 30 and commencing May 1 and ending October 31 of each year. As of the date of this Quarterly Report on Form 10-Q, the Company has suspended the 2018 ESPP until further notice.

Income Tax Expense

Income Tax Expense	6 Months Ended
	Jun. 30, 2021
Income Tax Expense
Income Tax Expense	9. Income Tax Expense For the three and six months ended June 30, 2020 the Company recorded a tax expense of $0.1 million and $0.3 million, respectively. For the three and six months ended June 30, 2021 the Company recorded a tax expense of $0.6 million and $0.8 million, respectively. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax bases of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, including the Company’s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of its deferred tax assets. On the basis of this evaluation the Company has recorded a valuation allowance against all of its deferred tax assets at June 30, 2021 and December 31, 2020.

Earnings (Loss) per Share

Earnings (Loss) per Share	6 Months Ended
	Jun. 30, 2021
Earnings (Loss) per Share
Earnings (Loss) per Share	10. Earnings (Loss) per Share Basic and diluted loss per share For the three and six months ended June 30, 2020 and 2021, basic and diluted net loss per share was determined by dividing net loss attributable to shareholders by the weighted average number of shares outstanding during the period. Diluted net loss per share is the same as basic net loss per share during the periods presented as the effects of the Company’s potential ordinary share equivalents are antidilutive since the Company had net losses for each period presented below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ June 30, ​ June 30, (in thousands, except per share data) 2020 2021 2020 2021 Net loss for the period $ (15,441) ​ $ (11,754) ​ $ (38,700) ​ $ (25,735) Weighted average number of shares outstanding 11,277,825 ​ 40,573,848 ​ 10,368,670 ​ 33,532,837 Basic and diluted loss per share $ (1.37) ​ $ (0.29) ​ $ (3.73) ​ $ (0.77) ​ The following ordinary share equivalents were excluded from the calculations of diluted earnings per share as their effect would be anti-dilutive since the Company had net losses for each period presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ June 30, ​ June 30, ​ 2020 2021 2020 2021 Stock option awards 1,027,485 ​ 948,682 ​ 1,027,485 ​ 948,682 Restricted share units 189,398 ​ 741,484 ​ 189,398 ​ 741,484 Warrants 5,438,842 ​ 10,619,347 ​ 5,438,842 ​ 10,619,347 ​

Significant Arrangements and Li

Significant Arrangements and License Agreements	6 Months Ended
	Jun. 30, 2021
Significant Arrangements and License Agreements
Significant Arrangements and License Agreements	11. Significant Arrangements and License Agreements China Region License Agreement In March 2018, the Company entered into the China Region License Agreement, with Sinovant Sciences, Ltd., or Sinovant, an affiliate of Roivant Sciences, Ltd., to develop and commercialize lefamulin in the greater China region. As part of the China Region License Agreement, Nabriva Therapeutics Ireland DAC and Nabriva Therapeutics GmbH, the Company’s wholly owned subsidiaries, granted Sinovant an exclusive license to develop and commercialize, and a non-exclusive license to manufacture, certain products containing lefamulin, or the China Region Licensed Products, in the People’s Republic of China, Hong Kong, Macau, and Taiwan, together the Territory. In May 2021, the Company entered into an assignment, assumption and novation agreement, or the Assignment Agreement, pursuant to which the Company consented to the assignment by Sinovant, an affiliate of Roivant Sciences, Ltd., of the China Region License Agreement to develop and commercialize lefamulin in the greater China region to Sumitomo Pharmaceuticals (Suzhou), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”). Pursuant to the Assignment Agreement, the Company agreed to release Sinovant and its affiliates from their obligations under the China Region License Agreement and consented to Sumitomo Pharmaceuticals (Suzhou)’s assumption of such obligations. In addition, Sumitomo Dainippon Pharma Co., Ltd., or Sumitomo, has agreed to guarantee all of the obligations of Sumitomo Pharmaceuticals (Suzhou) under the China Region License Agreement. Under the China Region License Agreement, Sumitomo Pharmaceuticals (Suzhou) and the Company’s subsidiaries have established a joint development committee, or the JDC, to review and oversee development and commercialization plans in the Territory. The China Region License Agreement includes milestone events consisting of a non-refundable $5.0 million upfront payment, an additional $91.5 million in milestone payments upon the achievement of certain regulatory and commercial milestone events related to lefamulin for CABP, plus an additional $4.0 million in milestone payments if any China Region Licensed Product receives a second or any subsequent regulatory approval in the People’s Republic of China. The Company has received the $5.0 million upfront payment, a $1.5 million payment for the submission of a clinical trial application, or CTA, by Sinovant to the Chinese Food and Drug Administration, which was received in the first quarter of 2019 and a $5.0 million milestone payment in the third quarter of 2019 in connection with the FDA approval for lefamulin. The Company will also be eligible to receive low double-digit royalties on sales, if any, of China Region Licensed Products in the Territory. In December 2020, the Company announced the restructuring of its China Region License Agreement. The restructured agreement provided for additional manufacturing collaboration and regulatory support to be provided to the contract counterparty by the Company that is expected to help expedite the delivery of XENLETA to patients in greater China. The restructured agreement also accelerated $3.0 million of the $5.0 million milestone payment to the Company that was previously payable upon regulatory approval of XENLETA in China, including a non-refundable upfront payment of $1.0 million which was received in the fourth quarter of 2020 and a $1.0 million milestone achieved during the first quarter of 2021. As of June 30, 2021, management determined that the remaining $1.0 million milestone payment was probable of achieving and therefore the Company is recognizing the $3.0 million of accelerated payments under the restructured agreement as collaboration revenue in the consolidated statements of operations over the estimated period the manufacturing collaboration and regulatory support will be provided to the contract counterparty, which was $1.3 million during the six months ended June 30, 2021, based on the proportional performance of the underlying performance obligation. The remaining milestones of $86.0 million are tied to additional regulatory approvals and annual sales targets. The future regulatory and commercial milestone payments under the China Region License Agreement will be recorded during the period the milestones become probable of achievement. Except for the manufacturing collaboration and regulatory support discussed above, Sumitomo Pharmaceuticals (Suzhou) will be solely responsible for all costs related to developing, obtaining regulatory approval of and commercializing China Region Licensed Products in the Territory and is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize China Region Licensed Products in the Territory. The Company is obligated to use commercially reasonable efforts to supply, pursuant to supply agreements to be negotiated by the parties, to Sumitomo Pharmaceuticals (Suzhou) a sufficient supply of lefamulin for Sumitomo Pharmaceuticals (Suzhou) to manufacture finished drug products for development and commercialization of the China Region Licensed Products in the Territory. Unless earlier terminated, the China Region License Agreement will expire upon the expiration of the last royalty term for the last China Region Licensed Product in the Territory, which the Company expects will occur in 2033. Following the expiration of the last royalty term, the license granted to Sumitomo Pharmaceuticals (Suzhou) will become non-exclusive, fully-paid, royalty-free and irrevocable. The China Region License Agreement may be terminated in its entirety by Sumitomo Pharmaceuticals (Suzhou) upon 180 days’ prior written notice at any time. Either party may, subject to specified cure periods, terminate the China Region License Agreement in the event of the other party’s uncured material breach. Either party may also terminate the China Region License Agreement under specified circumstances relating to the other party’s insolvency. The Company has the right to terminate the China Region License Agreement immediately if Sumitomo Pharmaceuticals (Suzhou) does not reach certain development milestones by certain specified dates (subject to specified cure periods). The China Region License Agreement contemplates that the Company will enter into ancillary agreements with Sumitomo Pharmaceuticals (Suzhou), including clinical and commercial supply agreements and a pharmacovigilance agreement. Sunovion License Agreement In March 2019, the Company entered into the Sunovion License Agreement with Sunovion. As part of the Sunovion License Agreement, Nabriva Therapeutics Ireland DAC, the Company’s wholly owned subsidiary, granted Sunovion an exclusive license under certain patent rights, trademark rights and know-how to commercialize the Licensed Products in Canada in all uses in humans in CABP and in any other indication for which the Licensed Products have received regulatory approval in Canada. Under the Sunovion License Agreement, Sunovion and DAC established a joint development committee (the “Sunovion JDC”), to review and oversee regulatory approval and commercialization plans in the Territory. Sunovion will be solely responsible for all costs related to obtaining regulatory approval of and commercializing Licensed Products in the Territory and is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize Licensed Product in the Territory. On November 7, 2019, the Company, through Sunovion, submitted a NDS. Health Canada determined there was a screening deficiency in December 2019 and a response from the Company/Sunovion was provided on December 18, 2019 and acknowledged by Health Canada on January 13, 2020. The NDS approval occurred on July 10, 2020. The Company identified two performance obligations at inception: (1) the delivery of the exclusive license to Sunovion, which the Company has determined is a distinct license of functional intellectual property that Sunovion has obtained control of; and, (2) the participation in the Sunovion JDC. The $1.0 million non-refundable upfront payment was allocated entirely to the delivery of the license as the Sunovion JDC deliverable was deemed to be de minimis. With the NDS approval that occurred on July 10, 2020, the Company received a regulatory milestone payment of $0.5 million. Any future regulatory and commercial milestone payments under the Sunovion License Agreement will be recorded during the period the milestones become probable of achievement. Sales Promotion and Distribution Agreement with Merck & Co. On July 15, 2020, the Company entered into a Sales Promotion and Distribution Agreement, or the Distribution Agreement, with MSD International GmbH, or MSD, and Merck Sharp & Dohme Corp., or Supplier, each a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Under the Distribution Agreement, upon satisfaction of certain specified conditions, MSD appointed the Company as its sole and exclusive distributor of certain products containing tedizolid phosphate as the active ingredient (marketed and sold by Supplier and MSD prior to the effective date of the Distribution Agreement under the trademark SIVEXTRO®) for injection, intravenous use and oral use, or the Products, in final packaged form labeled with the Company’s National Drug Code numbers in the United States and its territories, or the Territory. As of April 12, 2021, the Company began exclusive distribution of SIVEXTRO in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible Gram-positive microorganisms. Under the Distribution Agreement and subject to the fulfillment of certain conditions, including the Company having engaged sufficient sales representatives, restrictions relating to travel and physician office access in the Territory due to COVID-19 having continued to decrease in a sufficient portion of the Territory so as not to hinder the successful detailing of SIVEXTRO, the Company is granted the right by MSD initially to promote the Products in the Territory and, upon satisfaction of additional conditions, including an increase in sales representatives, the right to exclusively distribute the Products in the Territory, including the sole right and responsibility to fill orders with respect to the Products in the Territory. The Company has successfully satisfied those conditions, including the increase in the number of sales representatives, and began filling orders of SIVEXTRO with the Company´s own Nabriva NDC beginning April 12, 2021. Subject to applicable law, the Company is entitled to determine the final selling prices of the Products charged by the Company to its customers at its sole discretion, subject to an overall annual limit on price increases, and will be solely responsible for sales contracting and all market access activities, including bidding, hospital listing and reimbursement. The Company is responsible for all costs related to the promotion, sale and distribution of the Products by the Company, as well as all costs required to meet the Company’s staffing obligations under the Distribution Agreement. The Company is obligated to use commercially reasonable efforts to promote and distribute the Products and to maximize the sales of the Products throughout the Territory. The Company has agreed to employ a sales force or retain the services of a contract sales organization to fulfill its obligations under the Distribution Agreement. In September 2020, the Company began a small and focused sales effort, by utilizing 15 sales representatives in a virtual and in-person community-based sales effort with Amplity Health. The Company expanded this effort to 60 sales representatives in November 2020 and the Company may expand it further in 2021. Named Patient Program Agreement with WE Pharma Ltd. On June 30, 2020 the Company announced that WE Pharma Ltd., or WEP Clinical, a specialist pharmaceutical services company, had signed an exclusive agreement with the Company to supply XENLETA on a named patient or expanded access basis in certain countries outside of the US, China and Canada. The Named Patient Program, or NPP, is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available and have an unmet medical need.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies
Commitments and Contingencies	12. Commitments and Contingencies Legal Proceedings On May 8, 2019, a putative class action lawsuit was filed against the Company and its Chief Executive Officer in the United States District Court for the Southern District of New York, captioned Larry Enriquez v. Nabriva Therapeutics PLC, and Ted Schroeder, No. 19-cv-04183. The complaint purported to be brought on behalf of shareholders who purchased the Company's securities between November 1, 2018 and April 30, 2019. The complaint generally alleged that the Company and its Chief Executive Officer violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and/or misleading statements and omitting to disclose material facts concerning the Company's submission of an NDA to the FDA for marketing approval of CONTEPO for the treatment of cUTI in the United States and the likelihood of such approval. The complaint sought unspecified damages, attorneys' fees, and other costs. On May 22, 2019, a second putative class action lawsuit was filed against the Company and its Chief Executive Officer in the United States District Court for the Southern District of New York, captioned Anthony Manna v. Nabriva Therapeutics PLC, and Ted Schroeder, No. 19-cv-04713. The complaint purported to be brought on behalf of shareholders who purchased the Company's securities between November 1, 2018 and April 30, 2019. The allegations made in the Manna complaint were similar to those made in the Enriquez complaint, and the Manna complaint sought similar relief. On May 24, 2019, these two lawsuits were consolidated by the court. The court appointed a lead plaintiff and approved plaintiff's selection of lead counsel on July 22, 2019. On September 23, 2019, plaintiff filed an amended complaint, adding the Company's former Chief Financial Officer and Chief Medical Officer as defendants; the amended complaint purports to be brought on behalf of shareholders who purchased the Company's securities between January 4, 2019 through April 30, 2019, and otherwise includes allegations similar to those made in the original complaints and seeks similar relief. The Company's pre-motion letter to dismiss the amended complaint was due to plaintiff on October 21, 2019, and plaintiff responded to the Company via a letter on November 4, 2019. On November 18, 2019, the Company filed a pre-motion letter to dismiss with the Court, seeking leave to move to dismiss and setting forth why a motion to dismiss is warranted. On April 28, 2020, the Court dismissed the amended complaint without prejudice and granted plaintiff twenty days to show cause why the lawsuit should not be dismissed with prejudice. On May 8, 2020, the Court granted plaintiff a 21-day extension to show cause. On June 8, 2020, plaintiff filed a letter application to the court seeking leave to file a proposed second amended complaint, and on June 23, 2020, the court directed plaintiff to file the proposed second amended complaint. Plaintiff did so on June 24, 2020. The Company filed an answer to the second amended complaint on July 8, 2020. On October 21, 2020, the parties mediated this case and reached a settlement. On January 28, 2021, the court preliminarily approved the settlement. On May 14, 2021, the court issued an order and final judgment granting final approval of the settlement, plaintiff’s application for attorneys’ fees and reimbursement of litigation expenses, and a reimbursement award for the lead plaintiff, and closed the case. The settlement will be covered in full by the Company’s directors’ and officers’ insurance. Other Commitments and Contingencies The Company has other contractual commitments related primarily to contracts entered into with contract research organizations and contract manufacturing organizations in connection with the conduct of clinical trials and other research and development activities. During the three months ended June 30, 2021, there were no material changes outside the ordinary course of the Company’s business to its contractual obligations relating to contract research organizations and contract manufacturing organizations. The Company has no contingent liabilities in respect of legal claims arising in the ordinary course of business.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events
Subsequent Events	13. Subsequent Events The Company has evaluated all subsequent events through the filing date of this Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of June 30, 2021, and events which occurred subsequently but were not recognized in the financial statements. There were no subsequent events which required recognition, adjustment to, or disclosure in the financial statements, except as described below. On August 4, 2021, our wholly-owned subsidiary, Nabriva Therapeutics Ireland DAC, entered into an amendment, or the First Amendment, to its API Supply Agreement, or the Hovione Supply Agreement, with Hovione Limited, or Hovione, which provides for the long-term commercial supply of the active pharmaceutical ingredients, or API, for XENLETA. Under the First Amendment, Hovione agreed to cancel our May 2021 purchase order for XENLETA API, which represented our minimum purchase requirement under the Hovione Supply Agreement. In addition, pursuant to the First Amendment, Hovione agreed to reduce our annual minimum purchase requirements for XENLETA API to no minimum purchase requirement in 2021, by 50% from 2022 to 2024 and by 25% in 2025, in consideration for cash payments from us totaling €3.2 million and the right to a low single-digit royalty on total net sales of XENLETA in the United States for a period commencing on August 4, 2021 and ending on November 22, 2030, or the Royalty Term, which royalty payments shall be no greater than an aggregate of €10.0 million. If the aggregate amount of royalties payments received by Hovione under the First Amendment is less than an aggregate of €4.0 million, we are obligated to pay Hovione the difference in a lump sum payment at the end of the Royalty Term. In addition, pursuant to the First Amendment, Hovione agreed to extend the duration of the Hovione Supply Agreement from November 22, 2025 to November 22, 2030 with annual minimum purchase requirements for 2026 to 2030 at the newly agreed annual minimum purchase amount for 2025. Pursuant to the First Amendment, upon the occurrence of certain events of insolvency for us, any unpaid minimum annual commitment amounts and royalty amounts under the agreement will become immediately due and payable. ​ ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Basis of Preparation	Basis of Preparation The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP, for interim financial information, and US Securities and Exchange Commission, or SEC, regulations for quarterly reporting. The unaudited consolidated financial statements include the accounts of Nabriva Therapeutics plc and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial information as of June 30, 2021 and for the three and six months ended June 30, 2020 and 2021 are unaudited. The December 31, 2020 balance sheet was derived from audited consolidated financial statements but does not include all disclosures required by US GAAP. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2021 and results of operations for the three and six months ended June 30, 2020 and 2021. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 contained in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 11, 2021. The Company’s significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company has not adopted any new accounting pronouncements for the six months ended June 30, 2021.

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory
Schedule of inventory	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ December 31, ​ ​ June 30, (in thousands) ​ 2020 ​ ​ 2021 Raw materials $ 952 ​ $ 1,379 Work in process 4,608 ​ 7,014 Finished goods 263 ​ 1,721 Total Inventory $ 5,823 ​ $ 10,113

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Measurement
Schedule of the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ 16 ​ — ​ — ​ 16 Total Assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 Total June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalent: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market fund ​ $ 8,050 ​ $ — ​ $ — $ 8,050 Short term investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Term deposits ​ ​ 16 ​ — ​ — ​ 16 Total Assets ​ $ 8,066 ​ $ — ​ $ — $ 8,066

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ June 30, (in thousands) ​ 2020 ​ 2021 Research and development related costs ​ $ 1,055 ​ $ 814 Payroll and related costs ​ 4,049 ​ 3,747 Accounting, tax and audit services ​ 470 ​ 500 Manufacturing and inventory ​ ​ 4,779 ​ ​ 4,435 Accrued gross to net ​ ​ 662 ​ ​ 3,482 Other ​ 1,829 ​ 2,265 Total other current liabilities ​ $ 12,844 ​ $ 15,243

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt
Schedule of long-term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ As of ​ ​ ​ December 31, ​ ​ June 30, (in thousands) ​ 2020 ​ 2021 Term loan payable $ 5,000 $ 5,000 End of term fee ​ ​ 2,048 ​ ​ 2,188 Unamortized debt issuance costs ​ (206) ​ (193) Carrying value of term loan ​ ​ 6,842 ​ ​ 6,995 Other long-term debt ​ ​ 885 ​ ​ 874 Less: Amounts due within one year ​ ​ (2,041) ​ ​ (1,823) Total long-term debt $ 5,686 $ 6,046
Schedule of maturities of long-term debt	​ ​ ​ ​ ​ (in thousands) ​ ​ ​ 2021 $ — 2022 ​ $ 3,795 2023 ​ $ 4,811

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue
Summary of revenue by type	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, (in thousands) 2020 2021 2020 2021 Product revenue, net ​ $ (48) ​ $ 6,940 ​ $ 108 ​ $ 7,070 Collaboration revenues ​ ​ 7 ​ ​ 813 ​ ​ 152 ​ ​ 2,815 Research premium ​ ​ 301 ​ ​ 490 ​ ​ 591 ​ ​ 792 Government grants ​ 227 ​ — ​ 425 ​ 95 Total ​ $ 487 ​ $ 8,243 ​ $ 1,276 ​ $ 10,772
Summary of gross-to-net ("GTN") adjustments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, (in thousands) ​ 2020 2021 2020 2021 Product revenue, gross ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ SIVEXTRO ​ $ — ​ $ 10,287 ​ $ — ​ $ 10,287 XENLETA ​ ​ 149 ​ ​ 120 ​ ​ 398 ​ ​ 310 Total product revenue, gross ​ ​ 149 ​ 10,407 ​ 398 ​ 10,597 GTN accruals ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Chargebacks and cash discounts ​ (5) ​ (222) ​ (13) ​ (228) Medicaid and Medicare rebates ​ ​ (18) ​ ​ (1,003) ​ ​ (46) ​ ​ (1,018) Other returns, rebates, discounts and adjustments ​ ​ (35) ​ ​ (2,196) ​ ​ (92) ​ ​ (2,235) Total GTN accruals ​ ​ (58) ​ ​ (3,421) ​ ​ (151) ​ ​ (3,481) Product revenue ​ ​ 91 ​ ​ 6,986 ​ ​ 247 ​ ​ 7,116 Adjustments to prior period accruals ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns reserve (1) ​ ​ (349) ​ ​ (132) ​ ​ (349) ​ ​ (132) GTN accrual adjustments ​ ​ 210 ​ ​ 86 ​ ​ 210 ​ ​ 86 Product revenue, net ​ $ (48) $ 6,940 $ 108 $ 7,070

Share-Based Payments (Tables)

Share-Based Payments (Tables)	6 Months Ended
	Jun. 30, 2021
Stock Option Plan 2015
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in ​ intrinsic SOP 2015 ​ Options $ per share value Outstanding as of January 1, 2021 ​ 202,374 ​ 82.71 ​ Granted ​ — ​ — ​ ​ Exercised ​ — ​ — ​ ​ Forfeited ​ (32,824) 88.93 ​ ​ Outstanding as of June 30, 2021 ​ 169,550 81.51 ​ $ — Vested and exercisable as of June 30, 2021 ​ 169,141 81.48 ​ $ —
2017 Share Incentive Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ ​ Aggregate ​ ​ ​ ​ price in $ ​ ​ intrinsic 2017 Plan Options per share ​ value Outstanding as of January 1, 2021 442,844 ​ 30.89 Granted — ​ — Exercised — ​ — Forfeited (101,204) ​ 32.82 ​ ​ Outstanding as of June 30, 2021 341,640 ​ 30.31 ​ $ — Vested and exercisable as of June 30, 2021 231,403 ​ 34.75 ​ $ —
Summary of information regarding restricted stock awards	​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ average fair 2017 Plan RSUs ​ value in $ per share Outstanding as of January 1, 2021 151,269 ​ 14.56 Granted — ​ — Vested and issued (42,752) ​ 13.98 Forfeited (30,640) ​ 13.62 Outstanding as of June 30, 2021 77,877 ​ 14.19
2019 Inducement Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2019 Inducement Plan Options per share value Outstanding as of January 1, 2021 25,815 ​ 19.04 ​ ​ Granted — ​ — ​ ​ Exercised — ​ — ​ ​ Forfeited (13,053) ​ 18.20 ​ ​ ​ Outstanding as of June 30, 2021 12,762 ​ 19.90 ​ $ — Vested and exercisable as of June 30, 2021 8,510 ​ 19.16 ​ $ —
2020 Share Incentive Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2020 Plan Options per share value Outstanding as of January 1, 2021 296,805 ​ 10.18 ​ Granted 21,000 ​ 1.39 ​ Exercised — ​ — ​ Forfeited (107,325) ​ 5.70 ​ Outstanding as of June 30, 2021 210,480 ​ 9.87 ​ $ — Vested and exercisable as of June 30, 2021 — ​ — ​ $ —
Summary of assumptions used for valuation of options	​ ​ ​ ​ ​ Input parameters ​ ​ Expected volatility 77.3 % Expected term of options (in years) 5.5 ​ Range of risk-free interest rate 1.0 % Dividend yield — ​
2021 Inducement Share Incentive Plan
Share-Based Payments
Summary of information regarding stock option awards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ exercise ​ Aggregate ​ ​ ​ ​ price in $ ​ intrinsic 2021 Inducement Plan Options per share value Outstanding as of January 1, 2021 — — ​ Granted ​ 129,250 ​ 1.66 ​ Exercised ​ — ​ — ​ Forfeited ​ — ​ — ​ Outstanding as of June 30, 2021 129,250 ​ 1.66 ​ $ — Vested and exercisable as of June 30, 2021 — — ​ $ —
Summary of assumptions used for valuation of options	​ ​ ​ ​ Input parameters Expected volatility 75.3% - 76.3% Expected term of options (in years) 6.1 Risk-free interest rate 1.02% - 1.16% Dividend yield —

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings (Loss) per Share
Schedule of basic and diluted loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ June 30, ​ June 30, (in thousands, except per share data) 2020 2021 2020 2021 Net loss for the period $ (15,441) ​ $ (11,754) ​ $ (38,700) ​ $ (25,735) Weighted average number of shares outstanding 11,277,825 ​ 40,573,848 ​ 10,368,670 ​ 33,532,837 Basic and diluted loss per share $ (1.37) ​ $ (0.29) ​ $ (3.73) ​ $ (0.77)
Schedule of ordinary share equivalents excluded from the calculations of diluted loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ June 30, ​ June 30, ​ 2020 2021 2020 2021 Stock option awards 1,027,485 ​ 948,682 ​ 1,027,485 ​ 948,682 Restricted share units 189,398 ​ 741,484 ​ 189,398 ​ 741,484 Warrants 5,438,842 ​ 10,619,347 ​ 5,438,842 ​ 10,619,347

Organization and Business Act_2

Organization and Business Activities (Details) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	6 Months Ended
	May 31, 2021USD ($)shares	Nov. 30, 2020employee	Sep. 30, 2020employee	Mar. 31, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2020$ / shares	Jun. 30, 2019USD ($)
Liquidity
Percentage of lefamulin-treated patients	4.00%
Percentage of moxifloxacin-treated patients	10.00%
Percentage of TEASE's leading to discontinuation were subjects in both treatment arms	5.00%
Cash, cash equivalents and short-term investments					$ 61,300
Number of sales representatives | employee		60	15
Proceeds from at-the-market facility					$ 37,970	$ 3,688
Nominal value | $ / shares					$ 0.01		$ 0.01
Jefferies LLC | At-the-market offering
Liquidity
Maximum aggregate gross proceeds under the sales agreement								$ 50,000
Proceeds from at-the-market facility					$ 26,100
Net proceeds from sale of stock					$ 25,100
Jefferies LLC | At-the-market offering | Ordinary Shares
Liquidity
Number of shares issued | shares					14,318,074
Purchasers | Purchase agreement
Liquidity
Number of shares issued | shares				9,761,010
Net proceeds from sale of stock				$ 23,400
Proceeds from Issuance or Sale of Equity				$ 25,400
Number of ordinary shares that can be purchased by warrant holders | shares				4,880,505
Term				5 years
Ordinary Share Warrants | Purchasers | Purchase agreement
Liquidity
Number of ordinary shares that can be purchased by warrant holders | shares				300,000
Nominal value | $ / shares				$ 0.01
Share and warrant price | $ / shares				2.4525
Exercise price | $ / shares				$ 2.39
Pre-Funded Warrants | Purchasers | Purchase agreement
Liquidity
Number of ordinary shares that can be purchased by warrant holders | shares				600,000
Share and warrant price | $ / shares				$ 2.4425
Exercise price | $ / shares				$ 0.01
Open Market Sale Agreement | Jefferies LLC | Ordinary Shares
Liquidity
Number of shares issued | shares	5,925,699
Proceeds from at-the-market facility	$ 31,900
Aggregate gross sale proceeds for ordinary shares	33,700
Ordinary shares remained unsold	16,300
Open Market Sale Agreement | Jefferies LLC | Ordinary Shares | Maximum
Liquidity
Aggregate gross sale proceeds for ordinary shares	$ 50,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory
Raw materials	$ 1,379	$ 952
Work in process	7,014	4,608
Finished goods	1,721	263
Total Inventory	10,113	$ 5,823
Obsolete inventory non-cash reserve	$ 900

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Short-term investments:
Transfer of assets from Level 1 to 2	$ 0	$ 0
Transfer of assets from Level 2 to 1	0	0
Transfer of liabilities from Level 1 to 2	0	0
Transfer of liabilities from Level 2 to 1	0	0
Recurring
Cash equivalent:
Money market funds	8,050	8,050
Short-term investments:
Term deposits	16	16
Total Assets	8,066	8,066
Level 1 | Recurring
Cash equivalent:
Money market funds	8,050	8,050
Short-term investments:
Term deposits	16	16
Total Assets	$ 8,066	$ 8,066

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accrued expenses and other liabilities
Research and development related costs	$ 814	$ 1,055
Payroll and related costs	3,747	4,049
Accounting, tax and audit services	500	470
Manufacturing and inventory	4,435	4,779
Accrued gross to net	3,482	662
Other	2,265	1,829
Total other current liabilities	$ 15,243	$ 12,844

Debt - Summary (Details)

Debt - Summary (Details) - USD ($)	Jun. 02, 2021	Mar. 11, 2020	Feb. 29, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2018
Debt
Loss on extinguishment of debt						$ (2,757,000)
Term loan
Debt
End of term fee					$ 5,000,000		$ 5,000,000
Loan Agreement | Term loan
Debt
Maximum borrowing capacity								$ 75,000,000
Principal amount of advances outstanding		$ 35,000,000
Interest rate (as a percent)					9.80%
Fee due at maturity, as a percentage of aggregate advances					6.95%
The amount in excess of which prepayments may be made					$ 5,000,000
Repayment of debt		$ 30,000,000			30,000,000
Minimum cash and cash equivalents in accounts to be maintained	$ 3,000,000
Net product revenue	$ 15,000,000
Trailing period	3 months		6 months
Percent of net product revenue sales target		70.00%	80.00%
Minimum liquidity requirement			$ 40,000,000
Minimum amount to be maintained in cash and cash equivalents		$ 3,000,000
Maximum value of lender option to purchase equity securities					2,000,000
End of term loan charge payment		2,100,000
End of term loan charge		$ 300,000	$ 600,000
Loan origination costs					1,300,000
Initial fee paid to lender					700,000
Loss on extinguishment of debt				$ 2,700,000
End of term fee					$ 5,000,000
Loan Agreement | Term loan | Prime rate
Debt
Variable rate basis					interest minus 5.50%
Variable interest rate margin (as a percent)					9.80%
Variable rate adjustment (as a percent)					5.50%
Loan Agreement | Term loan | Initial Advance
Debt
Principal amount of advances outstanding								25,000,000
Loan Agreement | Term loan | Tranche 7 Advance
Debt
Maximum borrowing capacity								$ 5,000,000
Additional tranches					$ 5,000,000
Loan Agreement | Term loan | Prepayment during the first 12 months following initial closing
Debt
Prepayment penalty as a percentage of the amount being repaid					3.00%
Loan Agreement | Term loan | Prepayment after the first 12 months following initial closing but before 24 months
Debt
Prepayment penalty as a percentage of the amount being repaid					2.00%
Loan Agreement | Term loan | Prepayment after the first 24 months following initial closing but before maturity
Debt
Prepayment penalty as a percentage of the amount being repaid					1.00%

Debt - Long-Term Debt (Details)

Debt - Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Long-term debt
Less: Amounts due within one year	$ (1,823)	$ (2,041)
Total long-term debt	6,046	5,686
Maturities of long-term debt
2022	3,795
2023	4,811
Term loan
Long-term debt
Term loan payable	5,000	5,000
End of term fee	2,188	2,048
Unamortized debt issuance costs	(193)	(206)
Total long-term debt	6,995	6,842
Other long-term debt
Long-term debt
Total long-term debt	$ 874	$ 885

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended
	Dec. 31, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020
Revenue
Revenue accounted for under Topic 606		$ 8,243		$ 487		$ 10,772	$ 1,276
Product revenue, gross						17
Merck & Co | License Agreement
Revenue
Revenue accounted for under Topic 606						1,200
Collaboration revenue
Revenue
Revenue accounted for under Topic 606		813		7		2,815	152
Collaboration revenue | Sumitomo Pharmaceuticals (Suzhou) | License Agreement
Revenue
Revenue accounted for under Topic 606						1,600
Collaboration revenue - Upfront payment
Revenue
Revenue accounted for under Topic 606		6,940		(48)		7,070	108
Product revenue, gross		10,407		149		10,597	398
Collaboration revenue - Upfront payment | Sumitomo Pharmaceuticals (Suzhou) | License Agreement
Revenue
Revenue accounted for under Topic 606	$ 3,000		$ 1,000		$ 5,000
Research premium
Revenue
Revenue accounted for under Topic 606		$ 490		301		792	591
Government grants
Revenue
Revenue accounted for under Topic 606				$ 227		$ 95	$ 425

Revenue - Summary of Gross-To-N

Revenue - Summary of Gross-To-Net ("GTN") Adjustments (Details) - USD ($) $ in Thousands	Apr. 12, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Product revenue, gross				$ 17
Adjustments To prior period accruals
Product revenue, net		$ 8,243	$ 487	10,772	$ 1,276
Collaboration revenue - Upfront payment
Disaggregation of Revenue [Line Items]
Product revenue, gross		10,407	149	10,597	398
GTN accruals
Chargebacks and cash discounts		(222)	(5)	(228)	(13)
Medicaid and Medicare rebates		(1,003)	(18)	(1,018)	(46)
Other returns, rebates, discounts and adjustments		(2,196)	(35)	(2,235)	(92)
Total GTN accruals		(3,421)	(58)	(3,481)	(151)
Product revenue		6,986	91	7,116	247
Adjustments To prior period accruals
Returns reserve & GTN accrual adjustments		(132)	(349)	(132)	(349)
GTN accrual adjustments		86	210	86	210
Product revenue, net		6,940	(48)	7,070	108
XENLETA
Disaggregation of Revenue [Line Items]
Product revenue, gross		120	$ 149	$ 310	$ 398
Adjustments To prior period accruals
Percentage of inventory held				50.00%
SIVEXTRO
Disaggregation of Revenue [Line Items]
Product revenue, gross	$ 10,300	$ 10,287		$ 10,287

Share-Based Payments - SOP 2015

Share-Based Payments - SOP 2015 (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Stock Options
Additional disclosures
Share-based compensation expense	$ 100	$ 51	$ 200	$ 65
Stock Option Plan 2015
Options
Outstanding at beginning of year (in shares)			202,374
Forfeited (in shares)			(32,824)
Outstanding at end of year (in shares)	169,550		169,550
Vested and exercisable at end of year (in shares)	169,141		169,141
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)			$ 82.71
Forfeited (in dollars per share)			88.93
Outstanding balance at end of year (in dollars per share)	$ 81.51		81.51
Vested and exercisable balance at end of year (in dollars per share)	$ 81.48		$ 81.48
Stock Option Plan 2015 | Stock Options
Share-Based Payments
Vesting period			4 years
Additional disclosures
Share-based compensation expense	$ 38,000	$ 300	$ 169,000	$ 600
Weighted-average remaining contractual life			4 years 10 months 24 days
Total unrecognized compensation related to unvested options	$ 3		$ 3
Recognition period			1 month 6 days
Stock Option Plan 2015 | Stock Options | Vesting period, year one
Share-Based Payments
Percentage that vests during the period			25.00%
Stock Option Plan 2015 | Stock Options | Vesting period, years 2-4
Share-Based Payments
Percentage that vests during the period			75.00%
Monthly vesting percentage			2.083%
Stock Option Plan 2015 | Maximum | Stock Options
Share-Based Payments
Exercise period			10 years

Share-Based Payments - 2017 Sha

Share-Based Payments - 2017 Share Incentive Plan (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2018tranche
Fair Value Assumptions
Expected volatility (as a percent)			77.30%
Expected term of options (in years)			5 years 6 months
Risk-free interest rate (as a percent)			1.00%
Minimum
Fair Value Assumptions
Expected volatility (as a percent)			75.30%
Risk-free interest rate (as a percent)			1.02%
Maximum
Fair Value Assumptions
Expected volatility (as a percent)			76.30%
Risk-free interest rate (as a percent)			1.16%
Stock Options
Stock-Based Compensation Expense
Share-based compensation expense | $	$ 100	$ 51	$ 200	$ 65
2017 Share Incentive Plan
Options
Outstanding at beginning of year (in shares) | shares			442,844
Forfeited (in shares) | shares			(101,204)
Outstanding at end of year (in shares) | shares	341,640		341,640
Vested and exercisable at end of year (in shares) | shares	231,403		231,403
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share) | $ / shares			$ 30.89
Forfeited (in dollars per share) | $ / shares			32.82
Outstanding balance at end of year (in dollars per share) | $ / shares	$ 30.31		30.31
Vested and exercisable balance at end of year (in dollars per share) | $ / shares	$ 34.75		$ 34.75
2017 Share Incentive Plan | Stock Options
Fair Value Assumptions
Weighted-average remaining contractual life			7 years 6 months
Stock-Based Compensation Expense
Share-based compensation expense | $	$ 300	500	$ 600	1,100
Unrecognized compensation expense
Total unrecognized compensation related to unvested options | $	1,400		$ 1,400
Recognition period			1 year 2 months 12 days
2017 Share Incentive Plan | Restricted Stock Units ("RSUs")
Share-Based Payments
Fair Value | $			$ 200
Stock-Based Compensation Expense
Share-based compensation expense | $	100	$ 400	300	$ 1,000
Unrecognized compensation expense
Unrecognized compensation costs | $	$ 400		$ 400
Recognition period			2 years 7 months 6 days
Restricted Stock Units
Percentage that vests during the period			25.00%
Number of shares outstanding | shares			151,269
Vested and issued | shares			(42,752)
Forfeited | shares			(30,640)
Number of shares outstanding | shares	77,877		77,877
weighted average fair value per share
Weighted average fair value at the beginning | $ / shares			$ 14.56
Vested and issued | $ / shares			13.98
Forfeited | $ / shares			13.62
Weighted average fair value at the end | $ / shares	$ 14.19		$ 14.19
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs")
Share-Based Payments
Number of vesting periods | tranche					3
Vesting period					6 months
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval
Restricted Stock Units
Percentage that vests during the period					50.00%
XENLETA | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval
Restricted Stock Units
Percentage that vests during the period					50.00%
CONTEPO | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval
Restricted Stock Units
Percentage that vests during the period					50.00%
CONTEPO | 2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval
Restricted Stock Units
Percentage that vests during the period					50.00%

Share-Based Payments - 2019 Ind

Share-Based Payments - 2019 Inducement Share Incentive Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Mar. 12, 2019
Fair Value Assumptions
Expected volatility (as a percent)			77.30%
Expected term of options (in years)			5 years 6 months
Risk-free interest rate (as a percent)			1.00%
Minimum
Fair Value Assumptions
Expected volatility (as a percent)			75.30%
Risk-free interest rate (as a percent)			1.02%
Maximum
Fair Value Assumptions
Expected volatility (as a percent)			76.30%
Risk-free interest rate (as a percent)			1.16%
Stock Options
Weighted average exercise price in $ per share
Share-based compensation expense	$ 100	$ 51	$ 200	$ 65
2019 Inducement Plan
Options
Outstanding at beginning of year (in shares)			25,815
Forfeited (in shares)			(13,053)
Outstanding at end of year (in shares)	12,762		12,762
Vested and exercisable at end of year (in shares)	8,510		8,510
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)			$ 19.04
Forfeited (in dollars per share)			18.20
Outstanding balance at end of year (in dollars per share)	$ 19.90		19.90
Vested and exercisable balance at end of year (in dollars per share)	$ 19.16		$ 19.16
Share-based compensation expense	$ 7		$ 23	$ 100
2019 Inducement Plan | Ordinary Shares
Share-Based Payments
Shares reserved for future issuance					200,000
2019 Inducement Plan | Stock Options
Fair Value Assumptions
Weighted-average remaining contractual life			8 years 2 months 12 days
Unrecognized compensation expense
Total unrecognized compensation related to unvested options	$ 53		$ 53
Recognition period			2 years

Share-Based Payments - Induceme

Share-Based Payments - Inducement Awards Outside of the 2019 Inducement Plan (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fair Value Assumptions
Expected volatility (as a percent)				77.30%
Expected term of options (in years)				5 years 6 months
Risk-free interest rate (as a percent)				1.00%
Inducement Awards Outside of the 2019 Inducement Plan
Share-Based Payments
Share-based compensation expense		$ 0.1	$ 0.1	$ 0.2	$ 0.2
Additional disclosures
Weighted-average remaining contractual life				7 years 1 month 6 days
Total unrecognized compensation related to unvested options		$ 0.5		$ 0.5
Recognition period				1 year 1 month 6 days
Inducement Awards Outside of the 2019 Inducement Plan | Vesting period, year one
Share-Based Payments
Percentage that vests during the period	25.00%
Inducement Awards Outside of the 2019 Inducement Plan | Vesting period, year two
Share-Based Payments
Percentage that vests during the period	75.00%
Monthly vesting period	36 months
Inducement Awards Outside of the 2019 Inducement Plan | Non-statutory option
Share-Based Payments
Vesting period	4 years
Options exercise price (in dollars per share)	$ 35.30
Exercise period	10 years
Options weighted average grant date fair value (in dollars per share)				$ 2.05
Inducement Awards Outside of the 2019 Inducement Plan | Non-statutory option | Chief Executive Officer
Share-Based Payments
Options granted during the period	85,000
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs")
Share-Based Payments
Options weighted average grant date fair value (in dollars per share)				$ 3.53
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs") | Chief Executive Officer
Share-Based Payments
Restricted stock granted during the period	15
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs") | Upon receipt of FDA approval
Share-Based Payments
Percentage that vests during the period	50.00%
Inducement Awards Outside of the 2019 Inducement Plan | Restricted Stock Units ("RSUs") | First anniversary of FDA approval
Share-Based Payments
Percentage that vests during the period	50.00%

Share-Based Payments - 2020 Sha

Share-Based Payments - 2020 Share Incentive Plan (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2020tranche$ / sharesshares	Mar. 04, 2020shares
Fair Value Assumptions
Expected volatility (as a percent)			77.30%
Expected term of options (in years)			5 years 6 months
Risk-free interest rate (as a percent)			1.00%
2020 Share Incentive Plan
Share-Based Payments
Options granted during the period			21,000
Exercise price (in dollars per share) | $ / shares			$ 1.39
Options
Outstanding at beginning of year (in shares)			296,805
Granted (in shares)			21,000
Forfeited (in shares)			(107,325)
Outstanding at end of year (in shares)	210,480		210,480		296,805
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share) | $ / shares			$ 10.18
Granted (in dollars per share) | $ / shares			1.39
Forfeited (in dollars per share) | $ / shares			5.70
Outstanding balance at end of year (in dollars per share) | $ / shares	$ 9.87		$ 9.87		$ 10.18
Additional disclosures
Weighted-average remaining contractual life			7 years 10 months 24 days
Total unrecognized compensation related to unvested options | $	$ 600		$ 600
Minimum
Fair Value Assumptions
Expected volatility (as a percent)			75.30%
Risk-free interest rate (as a percent)			1.02%
Maximum
Fair Value Assumptions
Expected volatility (as a percent)			76.30%
Risk-free interest rate (as a percent)			1.16%
Ordinary Shares | 2020 Share Incentive Plan
Share-Based Payments
Shares reserved for future issuance	657,575		657,575
Ordinary Shares | Maximum | 2020 Share Incentive Plan
Share-Based Payments
Shares reserved for future issuance						930,000
Stock Options
Share-Based Payments
Share-based compensation expense | $	$ 100	$ 51	$ 200	$ 65
Stock Options | 2020 Share Incentive Plan
Weighted average exercise price in $ per share
Weighted-average grant date fair value (in dollars per share) | $ / shares			$ 0.90
Additional disclosures
Recognition period			1 year 6 months
Restricted Stock Units ("RSUs") | 2020 Share Incentive Plan | Employees
Share-Based Payments
Options granted during the period					45,977
Number of vesting periods | tranche					3
Vesting period					6 months
Grant date fair value | $ / shares					$ 7.88
Options
Granted (in shares)					45,977
Restricted Stock Units ("RSUs") | 2020 Share Incentive Plan | Certain Employees
Share-Based Payments
Restricted stock granted during the period			341,935
Restricted Stock Units ("RSUs") | 2020 Share Incentive Plan | Chief Executive Officer
Share-Based Payments
Restricted stock granted during the period			7,000
Percentage that vests during the period			50.00%
Performance Based Restricted Stock Unit | 2020 Share Incentive Plan | Employees
Share-Based Payments
Options granted during the period					43,125
Share-based compensation expense | $	200		$ 300
Grant date fair value | $ / shares					$ 5.30
Options
Granted (in shares)					43,125
Additional disclosures
Total unrecognized compensation related to unvested RSUs | $	$ 1,300		$ 1,300
Recognition period			2 years

Share-Based Payments - 2021 Ind

Share-Based Payments - 2021 Inducement Share Incentive Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 09, 2020
Fair Value Assumptions
Expected volatility (as a percent)			77.30%
Expected term of options (in years)			5 years 6 months
Risk-free interest rate (as a percent)			1.00%
Minimum
Fair Value Assumptions
Expected volatility (as a percent)			75.30%
Risk-free interest rate (as a percent)			1.02%
Maximum
Fair Value Assumptions
Expected volatility (as a percent)			76.30%
Risk-free interest rate (as a percent)			1.16%
Stock Options
Weighted average exercise price in $ per share
Share-based compensation expense	$ 100	$ 51	$ 200	$ 65
2021 Inducement Share Incentive Plan
Options
Granted (in shares)			129,250
Outstanding at end of year (in shares)	129,250		129,250
Weighted average exercise price in $ per share
Granted (in dollars per share)			$ 1.66
Outstanding balance at end of year (in dollars per share)	$ 1.66		$ 1.66
Fair Value Assumptions
Expected term of options (in years)			6 years 1 month 6 days
2021 Inducement Share Incentive Plan | Maximum
Share-Based Payments
Term of Awards			ten years
2021 Inducement Share Incentive Plan | Ordinary Shares
Share-Based Payments
Shares reserved for future issuance	70,750		70,750		200,000
2021 Inducement Share Incentive Plan | Stock Options
Weighted average exercise price in $ per share
Share-based compensation expense	$ 8		$ 8
Weighted-average grant date fair value (in dollars per share)			$ 1.09
Fair Value Assumptions
Weighted-average remaining contractual life			9 years 1 month 6 days
Unrecognized compensation expense
Total unrecognized compensation related to unvested options	$ 142		$ 142
Recognition period			4 years

Share-Based Payments - Employee

Share-Based Payments - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - shares	1 Months Ended	6 Months Ended
	Aug. 31, 2018	Jun. 30, 2021
Share-Based Payments
Maximum number of shares authorized under plan (in shares)	50,000
ESPP Share Pool as a percentage of total number of ordinary shares outstanding		0.10%
Purchase discount as a percentage of current market price		15.00%

Income Tax Expense (Details)

Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Expense
Income tax benefit (expense)	$ 606	$ 119	$ 796	$ 271

Earnings (Loss) per Share - Bas

Earnings (Loss) per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic and diluted loss per share
Net loss for the period	$ (11,754)	$ (13,981)	$ (15,441)	$ (23,259)	$ (25,735)	$ (38,700)
Weighted average number of shares outstanding, Basic	40,573,848		11,277,825		33,532,837	10,368,670
Weighted average number of shares outstanding, Diluted	40,573,848		11,277,825		33,532,837	10,368,670
Basic (in dollars per share)	$ (0.29)		$ (1.37)		$ (0.77)	$ (3.73)
Diluted (in dollars per share)	$ (0.29)		$ (1.37)		$ (0.77)	$ (3.73)

Earnings (Loss) per Share - Ant

Earnings (Loss) per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Stock Options
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	948,682	1,027,485	948,682	1,027,485
Restricted Stock Units ("RSUs")
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	741,484	189,398	741,484	189,398
Warrants
Anti-dilutive stock options
Ordinary share equivalents excluded from the calculations of diluted earnings per share	10,619,347	5,438,842	10,619,347	5,438,842

Significant Arrangements and _2

Significant Arrangements and License Agreements (Details) $ in Thousands

Jul. 10, 2020USD ($)

Dec. 31, 2020USD ($)

Nov. 30, 2020employee

Sep. 30, 2020employee

Mar. 31, 2018USD ($)

Jun. 30, 2021USD ($)

Mar. 31, 2021USD ($)

Dec. 31, 2020USD ($)

Jun. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Mar. 31, 2019USD ($)

Jun. 30, 2021USD ($)

Jun. 30, 2020USD ($)

May 31, 2021USD ($)

License Agreement

Revenue accounted for under Topic 606

$ 8,243

$ 487

$ 10,772

$ 1,276

Number Of Sales Representatives | employee

60

15

Collaboration revenue - Upfront payment

License Agreement

Revenue accounted for under Topic 606

6,940

$ (48)

$ 7,070

$ 108

Sunovion Pharmaceutics Canada, Inc. | Collaboration revenue - Upfront payment

License Agreement

Revenue accounted for under Topic 606

$ 1,000

License Agreement | Sunovion Pharmaceutics Canada, Inc. | NDS Approval

License Agreement

Revenue accounted for under Topic 606

$ 500

License Agreement | Sumitomo Pharmaceuticals (Suzhou)

License Agreement

Upfront payment

$ 5,000

Notice period for termination of agreement

180 days

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Achievement of certain regulatory and commercial milestones

License Agreement

Maximum contingent milestone payment

91,500

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Subsequent regulatory approval

License Agreement

Maximum contingent milestone payment

$ 4,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Clinical trial application submission

License Agreement

Proceeds from license agreement, milestone

$ 1,500

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | FDA approval

License Agreement

Revenue accounted for under Topic 606

$ 5,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Approval of XENLETA

License Agreement

Revenue accounted for under Topic 606

$ 5,000

Remaining probable of achieving

$ 1,000

Additional revenue recognized

3,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Additional regulatory approvals and annual sales targets

License Agreement

Remaining milestone payments

$ 86,000

86,000

License Agreement | Sumitomo Pharmaceuticals (Suzhou) | Collaboration revenue - Upfront payment

License Agreement

Revenue accounted for under Topic 606

$ 3,000

$ 1,000

$ 5,000

Milestone achieved

$ 1,000

Performance obligation

$ 1,300

Commitments and Contingencies -

Commitments and Contingencies - Other Commitments and Contingencies (Details) $ in Millions	Jun. 30, 2021USD ($)	Apr. 28, 2020item	Mar. 08, 2020item	May 24, 2019lawsuit
Other Commitments and Contingencies
Number Of Lawsuits | lawsuit				2
Notice days granted to plaintiff		20
Number of extension to show cause notice days granted to plaintiff			21
Contingent liabilities | $	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - Hovione Supply Agreement [Member] - Subsequent Event € in Millions	Aug. 04, 2021EUR (€)
Subsequent Event [Line Items]
Cash payments made for amendment of agreement.	€ 3.2
Threshold Aggregate Royalty Payments	4
Maximum
Subsequent Event [Line Items]
Royalty Payment	€ 10